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ABSTRACT
The cancer stem cell hypothesis posits that cancer stem cells (CSCs) are the driving force
behind tumour progression and metastasis, making them ideal therapeutic targets. Previous
research identified Leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5) as a
marker of CSCs in colorectal cancer (CRC). However, it is not known whether more than one
CSC population exists in CRC. Identifying and targeting CSCs in CRC is important for
effective treatment of cancer patients. Here, I show that Keratin-19 (K19) labels intestinal
CSCs in mouse tumours that recapitulate the early stages of CRC. Moreover, selective ablation
of Lgr5 has no effect on tumour initiation or growth. These results demonstrate additional CSC
populations exist besides those labeled by Lgr5, which are important for tumour initiation and
growth. Consequently, these findings have important clinical implications for the development
of new therapies targeting CSCs.
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Chapter 1
INTRODUCTION
1.1 The Healthy Colon
1.1.1

Intestinal anatomy and function

The mammalian intestinal tract can be divided into the small intestine and colon, which are
two anatomically and functionally distinct segments (Barker et al., 2010). These segments
share the same basic structure: an outer, middle and inner layer (Barker et al., 2010). The outer
layer consists of smooth muscle that is innervated by the enteric nervous system (Barker et
al., 2010). This layer is responsible for rhythmic peristaltic movements that direct food along
the intestine (Barker et al., 2010). The middle layer consists of connective or stromal tissue
(Barker et al. 2010). This tissue contains nerves, lymphatic vessels and capillaries which
transport absorbed nutrients from the third structure, the innermost layer (Barker et al., 2010).
The inner layer is composed of an absorptive epithelial lining called the mucosa (Barker et al.,
2010). However, the architecture of the small intestine (duodenum, jejunum and ileum) and
colon varies significantly reflecting their distinct functions in vivo (Barker et al., 2010). The
luminal surface of the small intestine consists of a sheet of epithelial cells which are organized
into numerous finger-like protrusions called villi that project into the lumen (Clevers, 2013).
These villi maximize the available surface area for absorption, reflecting the major function
of the small intestine - absorption of nutrients and minerals (Clevers, 2013). Each villus is
surrounded at the base by multiple epithelial invaginations termed the crypts of Lieberkühn.
These crypts were named after the scientist who discovered them - Jonathan Nathanael
Lieberkühn (1711-1756) (Clevers, 2013). He injected wax into the small intestine and colon
to reveal anatomical structures (Clevers, 2013). In contrast, the major function of the colon is
dehydration and waste removal (Clevers, 2013). This is reflected by an essentially flat mucosal
surface, with multiple crypts that penetrate deep into the underlying submucosa (Clevers,
2013).
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Figure 1 | Anatomy of the small intestine and colon. The intestinal tract is divided into two
anatomically and functionally distinct segments: the small intestine (duodenum, jejunum,
ileum) and colon. The colonic epithelium contains an essentially flat mucosal surface with
multiple crypts that penetrate deep into the underlying submucosa. In contrast to the relatively
flat surface of the colonic epithelium, the intestinal epithelium contains many finger like
projections known as villi, surrounded by crypts. These anatomical differences reflect their
differences in function, as the colon functions to compact stool and the small intestine
functions to absorb nutrients. Cross sections of the colonic vs intestinal tissue highlight these
differences. Moreover, each layer of the intestinal tract: outer, middle and inner is clearly
defined. This figure was originally published online in Mayo Foundation for Medical
Education and Research. [https://www.mayoclinic.org/colon-and-small-intestine/img20008226] and the Department of Zoology and Environmental Management, Faculty of
Science, University of Kelaniya, Sri Lanka. Gastrointestinal histology. 2018
[http://science.kln.ac.lk/depts/zoology/index.php?option=com_content&view=article&id=4
6&Itemid=46]. The figure is being reproduced for educational purposes only and not for any
commercial use. Figure is included in the M.Sc. dissertation with attribution.

1.1.2

Intestinal architecture

The epithelial lining of the intestine and colon is subjected to extremely harsh environmental
conditions (Barker et al., 2012). As such, it is highly susceptible to mechanical-, chemical- and
pathogen-driven insults (Barker et al., 2012). This imposes a need for continuous renewal of
the simple columnar cells that line the villi and crypts (Barker et al., 2012). Structurally, the
intestinal epithelium is highly regulated, with up to ten crypts generating over 250 new
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epithelial cells per day (Clevers, 2013) allowing for the entire epithelium to renew itself every
3-5 days for the duration of our lifetime (Leblond & Stevens, 1948). Due to the harsh
conditions that exist in the intestinal lumen, this extreme turnover rate is necessary to maintain
intestinal tissue homeostasis (Barker et al., 2010).

The cells responsible for driving tissue regeneration are vigorously proliferating epithelial cells
– known as intestinal stem cells (ISCs) that reside at the bottom of crypts (Barker et al.,
2012). The ISC population is capable of self-renewal and asymmetric division and gives rise
to rapidly expanding progenitors known as transit amplifying (TA) cells (Barker et al., 2012).
TA cells in the crypt divide and move toward the crypt/villus border to differentiate into six
main epithelial cell types: enterocytes, enteroendocrine cells, goblet cells, tuft cells, Paneth
cells (small intestine) and deep secretory cells (colon), whose function is outlined below
(Figure 2) (Van der flier & Clevers, 2009). These differentiated epithelial cells continue
migrating up the villus axis until they undergo apoptosis and are shed into the lumen of the
intestine (Van der flier & Clevers, 2009). The only post-mitotic cell types excluded from this
upward mobility are the Paneth cells (small intestine) and deep secretory cells (colon) (Van
der flier & Clevers, 2009). They migrate to the crypt base, where they reside for 6-8 weeks
(Van der flier & Clevers, 2009).

Enterocytes
Enterocytes comprise the majority of differentiated cells found in the villi of the small
intestine (Clevers, 2013). They are characterized by a luminal brush border and function as
absorptive cells responsible for nutrient uptake (Clevers, 2013). Due to their cellular
organization, they also prevent microbes from entering the bloodstream as they are tightly
packed together forming cell-to-cell adhesions, which act as a protective epithelial barrier
(Clevers, 2013). Enterocytes can be identified histologically by the expression of the enzyme
alkaline phosphatase.

Enteroendocrine cells
In comparison to other differentiated cell types, enteroendocrine cells are more rare and are
found throughout the whole crypt-villus axis (Gunawardene, 2011). Their function is to secrete
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hormones that regulate numerous processes, such as controlling glucose levels and food intake,
as well as signaling to empty food from the stomach (Gunawardene, 2011). They can be
identified histologically by staining for the presence of secretory vesicles using Chromogranin
A.

Goblet cells
Goblet cells are found throughout the villus and secrete mucins, which function to aid in the
lubrication of the epithelium (Clevers, 2013). Mucins serve to protect the epithelial lining from
extreme mechanical stress that results from the movement of food through the intestine
(Clevers, 2013). Goblet cells have also been found to secrete trefoil proteins that contribute to
tissue repair (Mashimo et al. 1996). These cells can be identified histologically by staining for
mucins using Alcian Blue.

Tuft cells
Tuft cells are also referred to as brush cells and are found anywhere throughout the crypt-villus
axis (Middlehoff et al., 2017). Their exact function and importance for intestinal homeostasis
are controversial (Middlehoff et al., 2017). However, they may act as chemosensory cells that
detect and sense the luminal contents (Middlehoff et al., 2017). Tuft cells can be identified
histologically through staining for a variety of different markers including Doublecortin Like
Kinase 1 (DCLK-1) (Middlehoff et al., 2017).

Paneth cells
Paneth cells are found exclusively in the small intestine, where they reside at the base of the
intestinal crypt (Clevers, 2013). They protect the intestinal crypt by providing microbial
immunity through the secretion of a variety of antimicrobial peptides such as lysosomes and
defensins (Clevers, 2013). Paneth cells may also play a role in tissue maintenance through the
secretion of growth factors that support the ISC population (Clevers, 2013). Unlike the other
differentiated cell types, Paneth cells are long-lived (6-8 weeks) and migrate back down to the
crypt-villus axis as they differentiate (Clevers, 2013). They can be identified histologically by
the presence of eosinophilic granules or staining for secreted lysozyme.
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Deep crypt secretory cells
Deep crypt secretory cells (DCS) are found exclusively in the colon, where they reside at the
base of the crypt (Sasaki et al., 2016) They may represent the colonic counterpart of Paneth
cells (Sasaki et al., 2016). DCS cells can be identified through the expression of Reg4+ (Sasaki
et al., 2016).

Figure 2 | The intestinal and colonic epithelium. The intestinal epithelium consists of
crypts and villi. The crypt base contains rapidly cycling intestinal stem cells (ISCs) as well
as transit-amplifying (TA) progenitors. The major differentiated cell types are enterocytes,
enteroendocrine cells, goblet cells, tuft cells and Paneth cells. Except for Paneth cells, these
cell types migrate as clonal lineages to the tip of the villi in 4-5 days where they are shed
into the lumen. Post-mitotic Paneth cells are relatively long lived (6-8 weeks) and
intermingle at crypt bottoms to secrete ISC niche factors and support innate immunity. In
contrast to the small intestine the colonic epithelium has a flat epithelial surface and lacks
Paneth cells. Instead of Paneth cells, deep secretory crypt cells are thought to be responsible
for the ISC niche function. This figure was originally published in Nature. Vermeulen L.,
and Snippert H. J. Stem cell dynamics in homeostasis and cancer of the intestine. 2014;
14(7), 468-480. This figure is being reproduced for educational purposes only and not for
commercial use. Figure is included in the M. Sc. dissertation with attribution.
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1.1.3

Intestinal stem cells

Models of intestinal stem cell identity
Although it is widely accepted that intestinal stem cells are multipotent adult stem cells,
which give rise to all epithelial cell lineages, the exact identity of ISCs (location and gene
expression patterns) is controversial. Over time, technological innovation has enabled the
identification of multiple candidate stem cell populations and provided insight into the
function of the ISC compartment. However, the lack of definitive markers to identify ISCs
has been a major obstacle in the field of intestinal stem cell biology. This created a longlasting debate on the true identity of ISCs, which remains confusing partially due to the use
of many different terms for the same cell or cellular processes.

Previously, it was reported that ISCs can be categorized into two distinct populations: crypt
base columnar and +4 stem cells. This led to the emergence of two opposing intestinal stem
cell models: the stem cell zone model and the +4 model (Barker et al., 2010). The stem cell
zone model argues that crypt base columnar (CBC) stem cells are the actual stem cells,
which rapidly divide at the base of the crypt and are responsible for intestinal homeostasis
(Cheng & Leblond, 1974). In contrast, the +4 model argues that the actual stem cells
responsible for intestinal homeostasis reside at the +4 position as discovered by Potten and
colleagues (Potten et al. 1997; Barker et al., 2010). A number of different stem cell markers
have been proposed for each model, only to be refuted later, making this a dynamic and
evolving area of research.
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Crypt base columnar stem cells
The first marker for CBC cells, leucine-rich-repeat containing G-protein coupled receptor
5 (Lgr5), was identified as a Wnt target gene selectively expressed at the base of intestinal
crypts (Figure 5) (Barker et al., 2007; Stevens and Leblond, 1947; Koo and Clevers, 2014).
Lgr5-positive CBC cells are considered fast-cycling as they divide every day and are the
driving force of intestinal tissue renewal (Barker et al., 2010). Several experimental
approaches have been used to validate the stem cell-like nature of these cells that are
outlined below, including lineage tracing, gene expression studies, stem cell activity
assays, and in vitro organoid culture.

In vivo lineage tracing using the Lgr5 marker
The current ‘gold standard’ to identify candidate stem cells in their native
microenvironments is lineage tracing (Barker, 2013). In this technique, a permanent
heritable genetic mark, such as the expression of a fluorescent protein, is introduced into
candidate stem cells (Barker, 2013). Subsequently, these marks are inherited by
descendants of that cell enabling their characterization in the epithelium (Figure 3) (Barker,
2013). If the presence of all differentiated lineages is observed in a single traced clone that
is capable of long-term labelling of cell lineages, it may reveal multipotency and selfrenewal (Barker, 2013). Taken together, these characteristics fulfil the basic definition of
a stem cell, as a cell capable of self-renewal and multipotency (Barker, 2013). The stem
cell activity of Lgr5+ CBCs was confirmed via lineage tracing in mice, which demonstrated
that CBC cells produced clonal ribbons containing all the major epithelial cell lineages and
persisted for the lifetime of the mouse (Barker et al., 2007). These results validated Lgr5+
CBC cells as self-renewing multipotent adult intestinal stem cells (Barker et al., 2007).
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Figure 3 | Genetic lineage tracing using Lgr5. (A) Cre recombinase expression is spatially
restricted by expressing it under the control of a tissue-specific promoter (Lgr5), while
temporal restriction is achieved by fusion of a tamoxifen-responsive hormone-binding
domain of the estrogen receptor (Cre-ERT). To visualize Lgr5 expressing cells as well as
their progeny, the Cre construct was used in conjunction with a reporter gene LacZ. This
reporter is ubiquitously expressed under the control of the Rosa26 promoter and placed
downstream of a STOP codon flanked by cre recombinase recognition sites (loxp). In the
absence of tamoxifen, the Cre enzyme is in an inactive state. Therefore, no expression of
the reporter gene is observed due to the presence of the STOP codon upstream of the
reporter gene. (B) However, when tamoxifen is administered the Cre enzyme is activated
and capable of translocating to the nucleus to mediate recombination between the loxp sites
in Lgr5 expressing cells. As a consequence, the STOP codon is excised and the cells are
permanently marked by the reporter gene. Part of this figure was originally published in
Nature. Vermeulen L., and Snippert H. J. Stem cell dynamics in homeostasis and cancer of
the intestine. 2014; 14(7), 468-480. This figure is being reproduced for educational
purposes only and not for commercial use. Figure is included in the M. Sc. dissertation
with attribution. (C) Histological analysis of LacZ activity in the small intestine of Lgr5CreERT;Rosa26-RLZ mice one day after induction, five days after induction (D), and 60
days after induction (E) This figure was originally published in Nature. Barker et al.
Identification of stem cells in small intestine and colon by marker gene Lgr5. 449(7165),
10003. This figure is being reproduced for educational purposes only and not for
commercial use. Figure is included in the M. Sc. Dissertation with attribution.
Lgr5+ CBC stem cell expression signature
Through a combination of microarray and proteomic experimental techniques, researchers
were able to establish a molecular signature for Lgr5+ CBC stem cells (Munoz et al.,
2012;Van der Flier et al., 2007). Sorted intestinal Lgr5-eGFP stem cells (high eGFP
expression) and their progeny (low eGFP expression) were analyzed to reveal
approximately 500 differential genes upregulated in stem cells (Van der Flier et al., 2007).
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As expected, a strong Wnt signature was present, including many Wnt target genes such as
Achaete-scute complex homolog 2 (Ascl2), EphB2, and Tory and axis inhibition (axin)-2
(Van der Flier et al., 2007). Interestingly, this expression profile also revealed novel
markers of Lgr5+ CBCs including Olfactomedin 4 (Olfm4) and SPARC related modulator
calcium binding 2 (SMOC2), as well as ring finger 43 (Rnf43) (Van der Flier et al., 2007).

Regulation of CBC stem cell activity and fate
Many of the genes identified from the Lgr5+ CBC stem cell expression signature have been
used to provide functional insight into the regulation of intestinal stem cell activity and fate
in vivo. In particular, ASCL2 was found to be highly upregulated in the Lgr5+ stem cell
fraction and was identified as a critical regulator of intestinal stem cell fate (Van der Flier
et al., 2009). ASCL2 is commonly known as a transcription factor that promotes neuroblast
differentiation. However, conditional ablation of ASCL2 in the intestinal epithelium
resulted in a rapid loss of the stem cell compartment (Van der Flier et al., 2009). Two other
genes that were found to be highly expressed in stem cells were Rnf43 and Troy (Barker,
2013). These genes play an important role in regulating endogenous Wnt signaling which
is critical in the maintenance of the stem cell compartment. Accordingly, Lgr5 was
identified as a component of the Wnt signaling complex at the plasma membrane (Barker,
2013). Lgr5 recruits secreted Wnt agonists (roof plate-specific spondin (R-spondin) 1-4),
thus amplifying canonical Wnt signaling and ensuring stem cell homeostasis in vivo
(Barker, 2013).
In vitro culture of Lgr5+ CBC stem cells
Further proof of Lgr5 labelling a stem cell population arose from the development of a
novel in vitro method known as organoid culture. In this method, single Lgr5+ CBC cells
were isolated from Lgr5-eGFP reporter mice using fluorescence activated cell sorting
(FACS) and plated in a Matrigel-based three-dimensional culture system (Sato et al., 2009).
The Matrigel is supplemented with media that contains a cocktail of growth factors found
in the endogenous stem cell niche including: Noggin (a bone morphogenic protein
inhibitor), R-spondin (Wnt agonist), epidermal growth factor (EGF) and Notch ligand (Sato
et al., 2009). This generates self-renewing epithelial organoids also known as “mini-guts”
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that are organized into crypts (containing CBC cells intercalated with Paneth cells) and a
villus-like region (containing differentiated cell lineages) (Figure 4) (Sato et al., 2009).
This system was also adapted to culture the colonic epithelium. However, these cultures
require WNT3A in the media, most likely reflecting differences in the stem cell niche
between the small intestine and colon.

Figure 4 | Generation of organoids via intestinal stem cell culture. Isolated intestinal
crypts containing Lgr5+ CBC stem cells or purified Lgr5+ CBC stem cells are plated into
Matrigel containing Noggin, R-spondin1, EGF and Notch ligand. This results in the
generation of self-renewing epithelial organoids organized into crypt and villus like
domains. The crypts contain stem cells intercalated with Paneth cells at their base, while
the villi contain differentiated cell lineages. This protocol was adapted for culturing the
colonic epithelium, although these cultures require exogenous WNT3A. This figure was
originally published in Nature. Vermeulen L., and Snippert H. J. Stem cell dynamics in
homeostasis and cancer of the intestine. 2014; 14(7), 468-480. Modified figure shown here
is substantially different from the original and is being included for educational purposes
only.

+4 stem cells
A number of genes have been reported to selectively identify the +4 stem cell position
using in vivo lineage tracing including B cell-specific Moloney murine leukemia
integration-1 (BMI1), keratin-19 (K19) and homeodomain-only (HOPX), which are briefly
outlined below and in figure 5.

BMI1
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BMI1 was first implicated in regulating hematopoietic and neural stem cell regulation
through encoding a component of the Polycomb repressor complex (Sangiorgi & Capecchi,
2008). However, analysis of BMI1 expression in the small intestine using in situ
hybridization revealed that it was predominantly expressed at the +4 ISC position
(Sangiorgi & Capecchi, 2008). This was further validated using a Bmi1-eGFP reporter
mouse model (Tian, H. et al 2011), as well as in vivo fate-mapping studies using a Bmi1CreERT/R26R-lacz mouse model. These experiments demonstrated that BMI1+/ +4
position cells produced clonal ribbons containing all the major epithelial cell lineages and
persisted for the lifetime of the mouse (Tian, H. et al 2011), thus validating BMI1+/ +4
cells as self-renewing multipotent adult ISCs. Additionally, when BMI1+ cells were
ablated in vivo, epithelial renewal was prevented, suggesting BMI1+ ISCs play an
important role in intestinal homeostasis (Tian, H. et al 2011). Further evidence
demonstrated that isolated BMI1+ cells could generate epithelial organoids in culture that
capitulated functional intestinal tissue (Yan et al., 2012), providing support that BMI1
labels an ISC population.

K19
Keratin-19 (K19) was first implicated as a cytokeratin (a multigene family of intermediate
filaments), critical in the maintenance of the cytoskeleton but expressed in different
lineages in the epithelium (Moll et al., 1982). To investigate the role of K19 in the small
intestine and colon, a K19-mApple reporter mouse was generated. Upon histological
analysis of the small intestine and colon, K19-mApple was expressed at the +4-position
extending up the isthmus, labelling a population of cells including long-lived stem cells
that were distinct from rapidly cycling Lgr5+ CBC stem cells. Of note, unlike BMI1, K19
is expressed in both the small intestine and colon (Asfaha et al., 2015). Furthermore,
genetic lineage tracing experiments using K19-BAC-CreERT;R26-LacZ mice revealed
labelled cells expanded clonally and persisted for the lifetime of the mouse, consistent with
K19 labeling long-lived ISCs (Asfaha et al., 2015).

HOPX
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HOPX was first implicated in regulating developmental processes as the gene encodes an
atypical homeobox protein. However, analysis of HOPX expression in the intestine using
HOPX-Lacz reporter mice revealed it labels a +4 position ISC population that is quiescent
and radiation-resistant (Takeda et al., 2011). This was further validated through in vivo
lineage tracing studies using HOPX-CreERT;R26R-Lacz mice (Takeda et al., 2011). These
studies revealed reporter gene activation at the +4 position followed by the production of
clonal ribbons containing all the major epithelial cell lineages that persisted for the lifetime
of the mouse (Takeda et al., 2011). This indicated that HOPX labels a multipotent, selfrenewing adult ISC. When the progeny of HOPX+ cells were analyzed using expression
profiling, Lgr5 and other CBC genes were found to be highly expressed. This suggested
that HOPX is capable of giving rise to Lgr5+ CBC cells. Of note, when Lgr5+ CBC stem
cells were cultured they gave rise to HOPX+ cells (Takeda et al., 2011). These findings
support a unique model of ISC identity, whereby stem cell populations may interconvert.

Figure 5 |Markers & characteristics of intestinal stem cells. +4 ISC can be identified
through the markers K19, BMI1 and HOPX. This stem cell population is typically
characterized as label retaining, quiescent and damage resistant. CBC stem cells can be
identified through the expression of Lgr5 and OLFM4. This stem cell population is
typically characterized as proliferative and damage sensitive. This figure was originally
published in Nature. Vermeulen L., and Snippert H. J. Stem cell dynamics in homeostasis
and cancer of the intestine. 2014; 14(7), 468-480. Modified figure shown here is
substantially different from the original and is being included for educational purposes
only.
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Current view on intestinal stem cell identity
Although specific markers have been identified for both the CBC and +4 stem cell
populations, neither model has been definitively true. Recently, a more plastic model of
stem cell identity has emerged. In this model, the crypt base contains two types of ISCs (1)
the CBC stem cells that act as a dedicated and active ISC population responsible for daily
epithelial homeostasis, and (2) the relatively quiescent +4 cells, which act as a secondary
“reserve” stem cell population capable of activating upon tissue injury. Furthermore, this
model suggests that cells residing in the lower portion of the TA compartment may
dedifferentiate to acquire stem cell properties in the case of catastrophic injury to the crypt
base. Accordingly, it has been proposed that many of the markers discussed above define
pools of dedicated or reserve ISC that are selectively activated in response to various
injuries. Importantly, many irradiation-induced injury models have provided important
mechanistic insight into this theory. In one study, short-term loss of Lgr5+ CBC cells
through targeted conditional ablation in vivo, revealed no negative effects on the intestinal
epithelium despite the critical role of CBC cells in homeostasis (Tian et al., 2011). This
suggested that another damage-resistant “reserve” stem cell may be capable of maintaining
intestinal homeostasis (Tian et al., 2011). Based on the inherent characteristics of +4 ISCs
such as quiescence and radiation-resistance, they are the likely reserve stem cell candidates
(Yan et al., 2012). Moreover, there is evidence that BMI1 as well as K19 label a reserve
stem cell population as in vivo lineage tracing from BMI1 (Tian et al., 2011) and K19
(Asfaha et al., 2015) was observed following targeted ablation of the Lgr5+ CBC stem cell
population or radiation injury. Challenging the traditional models of ISC identity, these
findings support a unique model whereby epithelial homeostasis is maintained by a
heterogeneous pool of both dedicated and reserve ISCs.
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1.1.4

Signaling pathways involved in intestinal homeostasis

The maintenance of intestinal structure and function depends upon a delicate balance of
cell proliferation, migration and apoptosis that must be carefully regulated. These processes
are regulated by controlling gene expression through four main signaling pathways: Wnt,
Notch, TGFβ/BMP and the Hedgehog pathway that are outlined below, as well as in Figure
6.
Wnt
The Wnt signaling pathway plays an essential role in the maintenance of cellular hierarchy
throughout the intestinal and colonic epithelium. A gradient of Wnt activity is observed
along the crypt-villus axis, with the highest level of Wnt pathway activation occurring at
the base of the intestinal crypts where the ISC population resides (Spit et al., 2018). The
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ISC population remains in close contact to stromal tissue capable of providing an
abundance of Wnt factors (Spit et al., 2018). Subsequently, when a Wnt ligand binds to its
receptor complex containing Frizzled (FZ)/low-density lipoprotein (LDL) receptor-related
protein (LRP), a signal is transduced to intracellular proteins that stimulates interaction
between Dishevelled (Dsh) and Axin (Spit et al., 2018). This prevents the breakdown of βcatenin and results in an accumulation of β-catenin in the cytoplasm and nucleus. β-catenin
is then able to interact with a member of the lymphoid enhancer-binding factor 1 or T cellspecific transcription factor (LEF/TCF) to enhance transcription of Wnt target genes (Spit
et al., 2018).

A variety of Wnt target genes function to enhance cell proliferation, migration and
adhesion processes that are essential for intestinal and colonic epithelium homeostasis.
Thus, the expression of Wnt target genes increases the proportion of stem cells (Spit et al.,
2018). As cells differentiate and migrate up the crypt-villus axis towards the lumen of the
intestine, they lose their proximity to Wnt factors. In the absence of Wnt, a β-catenin
destruction complex is formed preventing the downstream activation of Wnt target genes
(Spit et al., 2018). Briefly, the intracellular proteins adenomatous polyposis coli (APC) and
Axin are phosphorylated by glycogen synthase kinase-3 (GSK3), resulting in the
breakdown of β-catenin (Spit et al., 2018). Subsequently, this decrease in Wnt signaling is
thought to drive differentiation of the intestinal and colonic epithelium. Interestingly,
conditional homozygous deletion of β-catenin in mice results in increased apoptosis,
catastrophic destruction of crypts, reduced numbers of goblet cells and detachment of entire
sheets of enterocytes (Sansom et al., 2004). These results highlight the important role of
Wnt in maintaining the ISC compartment.

Notch
Similar to Wnt signaling, Notch also plays a role in maintaining the undifferentiated and
proliferative stem cell compartment at the base of the crypt (Van der Fliers and Clevers,
2009). This is supported by the high levels of Notch ligands found at the base of the crypt
compared to the rest of the crypt-villus axis (Spit et al., 2018). In contrast to the Wnt
pathway, Notch signaling can only occur via direct cell-to-cell contact of adjacent cells
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(Spit et al., 2018). When Notch ligands (such as Jagged or Delta) interact with the Notch
receptor, two proteolytic cleavage events are initiated (Spit et al., 2018). Firstly, tumour
necrosis factor-α-converting enzyme (TACE), cleaves the extracellular domain of the
Notch receptor (Spit et al., 2018). Then a second cleavage event takes place, which frees
the Notch intracellular domain (NICD), enabling it to enter the nucleus (Spit et al., 2018).
Once NICD enters the nucleus, it is able to activate the transcription factor CSL, resulting
in the expression of Notch target genes (Spit et al., 2018). Similar to Wnt, Notch target
genes influence apoptosis, proliferation, spatial patterning and cell fate determination
(Artavanis-Tsakanoas et al., 1999). Inhibition of Notch signaling in mice results in a
decrease of epithelial stemness and an increase in the goblet cell population (Sikander et
al., 2010). This reinforces Notch’s role in maintaining the ISC compartment.
TGFβ/BMP
In contrast to Wnt and Notch signaling, the TGFβ/BMP signaling pathway is a negative
regulator of intestinal stem cell renewal (He et al., 2004; Spit et al., 2018). In this role, the
expression of TGFβ is concentrated at the villus tip where cells are differentiated and not
proliferating (Spit et al., 2018). TGFβ and BMP pathways are activated in a similar manner:
a ligand binds to the membrane-bound type II receptor that enables the type II receptor to
dimerize with type I receptors and phosphorylate its cytoplasmic domain (Spit et al., 2018).
Upon phosphorylation, type I receptors recruit and phosphorylate SMAD2/3 (TGFβ), or
SMAD1/5/8 (BMP) proteins (Spit et al., 2018). Once phosphorylated these complexes are
referred to as receptor regulated SMADS (R-SMADS) (Spit et al., 2018). To enable
translocation into the nucleus, R-SMADS dissociate from the receptor and form a complex
with SMAD4 (Spit et al., 2018). Once in the nucleus, SMAD4 interacts with regulatory
proteins to activate transcription factors and downstream TGFβ/BMP genes (Spit et al.,
2018). The target genes of the TGFβ/BMP pathways are most commonly associated with
inhibition of cellular growth and proliferation. Interestingly, inhibition of TGFβ/BMP
signaling in mice increases the proportion of stem and progenitor cell populations,
eventually leading to cancer (He et al., 2004). These findings highlight the inhibitory
function of this pathway under homeostatic conditions and explains the ability of
TGFβ/BMP to inactivate stem cells.
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Hedgehog
Hedgehog signaling has been found to primarily regulate the intestinal mesenchyme.
However, it plays an important role as an indirect regulator of BMP and Wnt signaling
(Kaestner et al., 1997; Spit et al., 2018). The hedgehog pathway is controlled by two
transmembrane proteins known as Patched and Smoothened. When a ligand (Sonic
Hedgehog (Shh), Indian Hedgehog (Ihh) or Desert hedgehog (Dhh)) binds to Patched,
Smoothened inhibition is prevented, allowing for active Smoothened to prevent
phosphorylation and degradation of Gli2/3 (Spit et al., 2018). Subsequently, Gli2/3 is able
to enter the nucleus and act as a transcription factor for Hedgehog target genes. In
particular, one important target gene of the Hedgehog pathway is FoxL1. FoxL1 has been
shown to regulate BMP and Wnt signaling (Kaestner et al. 1997). Interestingly, FoxL1
deficit results in increased intestinal epithelial proliferation and distorted crypt architecture
(Kaestner et al. 1997). More recently, Kosinski and colleagues demonstrated a similar
effect is caused by the loss of the Hedgehog ligand Ihh in the intestinal epithelium,
manifesting as increased proliferation and expansion of the ISC compartment (Kosinski et
al., 2010). The Hedgehog pathway also indirectly affects the ISC compartment through
modulation of the adjacent mesenchymal tissue that makes up the supportive structure of
the crypts (Kosinski et al., 2010). When Ihh was depleted, the mesenchymal architecture
was disrupted and the extracellular matrix deteriorated. This lead to a loss of crypt
architecture and an increase in the ISC population, highlighting the important link between
interactions of the epithelium and mesenchymal tissue in ISC homeostasis (Kosinski et al.,
2010).
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Figure 6 | The four main signaling pathways involved in intestinal homeostasis. From
left to right: WNT, Notch, TGFB/BMP and hedgehog signaling. These pathways all control
the expression of genes associated with homeostatic processes such as proliferation,
apoptosis, differentiation, growth and migration This figure was originally published in
Current molecular medicine. Radtke, F., Clevers, H. & Riccio, O. From gut homeostasis
to cancer. 2006; 6(3), 275-289. Modified figure shown here is different from the original
and is being included for educational purposes only.
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1.2 Colorectal Cancer
Colorectal cancer (CRC) is one of the most common cancers worldwide, with over 1.2
million new cases diagnosed each year (Zeuner et al., 2014). In Canada, CRC is highly
prevalent with an estimated 27,000 Canadians diagnosed in 2017 (Bromfield et al., 2017).
Although aggressive treatment options such as surgery, radiation and chemotherapy are
available, approximately 30-50% of patients will develop therapy-resistant CRC (TRCRC) leading to recurrent disease (Ragnahammar et al., 2001; O’Connell et al., 2008).
Unfortunately, when TR-CRC is treated unsuccessfully, recurrent tumours that arise are
often much more aggressive than primary tumours, resulting in poor survival rates
(O’Connell et al., 2008). Other factors that have been found to impact patient survival
include detection of CRC in advanced stages as well as high recurrence rates and tendency
to metastasize. Due to this, CRC remains the second and third leading cause of death in
men and women, respectively (Bromfield et al., 2017).
By etiology, human CRC can be classified as inherited, colitis-associated, or sporadic.
Inherited CRC can be categorized into: familial, hereditary nonpolyposis, familial
adenomatous polyposis (FAP) and rare CRC syndromes. Familial CRC accounts for 1030% of all CRC cases and is defined by family history of non-syndromic CRC (Figure 7)
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(Jasperson et al., 2010). It is caused by an accumulation of mutations in intestinal epithelial
cells and progresses through a well-characterized sequence (described in section 1.2.1)
(Jasperson et al., 2010). Hereditary nonpolyposis CRC (HNPCC) or Lynch syndrome
accounts for 5% of all CRC cases (Jasperson et al., 2010). It is an autosomal dominant
condition that is caused by mutations in genes involved in the DNA mismatch repair
pathway including MSH2, MLH1 and MSH6 (Jasperson et al., 2010). Familial
adenomatous polyposis (FAP) accounts for 5% of all CRC cases and is caused by a
germline mutation in the adenomatous polyposis coli gene (APC) (Jasperson et al., 2010).
A subset of inherited CRCs is very rare and accounts for 0.1% of all cases. These include
leiomyosarcomas, colorectal lymphomas, neuroendocrine tumours, as well as
gastrointestinal stromal tumours (GISTs) (Jasperson et al., 2010). Colitis-associated CRC
(CA-CRC) arises from areas of active colonic inflammation caused by inflammatory bowel
disease (IBD) and accounts for 2% of all CRC cases (Van Der Kraak et al., 2015). It is
caused by an accumulation of mutations in intestinal epithelial cells and progresses through
a well-characterized inflammation to dysplasia to carcinoma sequence (described in section
1.2.1) (Van Der Kraak et al., 2015). Lastly, the majority of colorectal cancer cases are
considered sporadic (~80%). However, the etiology of sporadic CRC remains elusive. In
addition to hereditary- or disease-related aspects, a likely contributing factor to the
development of CRC may be a number of lifestyle factors including: obesity, physical
inactivity, dietary influences and smoking (World Cancer Research Fund, 2011).
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Figure 7 | Etiology of colorectal cancer. The etiology of human CRC can be classified as
rare CRC syndromes (0.1%), colitis-related (2%), familial adenomatous polyposis (5%),
Hereditary nonpolyposis (5%), familial (10-30%) or sporadic (65-85%).

1.2.1

A model of colorectal carcinogenesis

Early observations in human cancers and animal models reported that a successive
accumulation of multiple genetic mutations is necessary to convert a normal human cell
into a cancer cell (Foulds, 1954; Nowell, 1976). Following these initial observations,
Fearon and Vogelstein proposed a model of colorectal carcinogenesis based on studies of
the frequency of gene mutations at various stages of progression in human tumours (Fearon
and Vogelstein, 1990). In this model, CRC development is a multistep process, whereby a
series of genetic mutations leads to progression from the normal intestinal epithelium to
dysplastic tissue to benign adenomas through to metastatic carcinoma (Figure 8). The
initial step in colorectal carcinogenesis involves loss of function of APC resulting in
constitutive activation of the Wnt-pathway and formation of a benign lesion (Fearon and
Vogelstein, 1990). This is followed by an activating mutation in the small GTPase KRAS
and subsequent inactivation of SMAD2/4 in adenomas and early carcinomas, respectively
(Fearon and Vogelstein, 1990). Lastly, inactivating mutation in p53 lead to invasion and
metastatic lesions (Fearon and Vogelstein, 1990) (Figure 8). Initial research on invasive
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carcinomas from familial and colitis-associated CRC showed a similar genetic pattern of
acquired mutations in APC, KRAS, SMAD2/4 and p53. This led to the assumption that
genes important in the initiation and progression of familial CRC were also important in
CA-CRC. Although the accumulated mutations were similar, the timing of these genetic
mutations was found to vary greatly between familial and CA-CRC. In CA-CRC, the order
of progression is reversed, whereby the initiating mutation tends to occur in p53, followed
by SMAD2/4, KRAS and lastly APC (Van Der Kraak et al., 2015). Interestingly, the
frequency of APC mutation in high grade dysplasia is also reduced (27.5%) compared to
non-CA-CRC adenomas (50%) (Foersch et al., 2014). Thus highlighting the genetic
differences in colorectal carcinogenesis between familial and colitis associated colorectal
cancer.

Figure 8| Model of colorectal carcinogenesis as proposed by Fearon and Vogelstein.
Progression from normal epithelium to colorectal cancer requires an accumulation of
mutations in particular genes that affect the balance between proliferation and apoptosis.
The steps shown above occur during the development of sporadic colorectal cancer in
normal colonic epithelium. However, not all colorectal tumours exhibit all the mutations
shown in the above figure. Part of this figure was originally published in Nature.
Vermeulen L., and Snippert H. J. Stem cell dynamics in homeostasis and cancer of the
intestine. 2014; 14(7), 468-480 and Nature reviews cancer. Davies, R. J., Miller, R., &
Coleman, N. Colorectal cancer screening: prospects for molecular stool analysis. 2005;
5(3), 199. Modified figure shown here is different from the original and is being included
for educational purposes only.
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1.2.2
Cell of origin theory
In colorectal cancer research, two theories about the cell of origin exist: the bottom-up and
top-down model. The bottom-up model proposes that stem cells are the cell of origin; i.e.
stem cells acquire the initial mutations necessary for malignant conversion (Visvader,
2011). Evidence for the malignant conversion of stem cells has been demonstrated using
mouse models that allow for the induction of specific mutations in ISCs. In 2009, Barker
et al. found that deleting the APC tumour suppressor gene in Lgr5-expressing CBC stem
cells lead to rapid adenoma formation throughout the small intestine and colon (Barker et
al., 2009). Further studies also demonstrated rapid adenoma formation upon aberrant Wnt
activation in BMI1+ and K19+ cells, supporting the bottom-up model as transformation
was initiated in a stem cell at the bottom of the crypt (Preston, Wong et al. 2003). In
contrast, the top-down model opposes the unidirectional development of tumours from
stem cells. In this model, transformation is initiated in a differentiated cell that spreads
laterally, thus initiating tumour growth from the top down. Recently, it was demonstrated
that loss of APC in a differentiated cell population followed by aberrant activation of
nuclear factor-κB (NF-κB) through intestinal inflammation or KRAS mutation, leads to
transformation of these cells (Schwitalla et al. 2013; Asfaha et al. 2015). However, APC
inactivation alone was not sufficient to initiate tumorigenesis. This suggests that additional
signals are required for malignant conversion of differentiated cells in the top-down model
of carcinogenesis.
1.2.3

Wnt signaling in cancer

Wnt target genes play a key role in a number of regulatory processes associated with
tumorigenesis, such as cell proliferation and adhesion (Staal et al., 2004). As such,
abnormalities in the Wnt pathway are closely associated with cancer including CRC (Bienz
and Clevers, 2000; Polakis, 2000). This important role of Wnt pathway in CRC was
highlighted by the detection of truncating mutations in the tumour suppressor gene APC in
1989 (Ashton-Rickardt et al., 1989). APC is an important negative regulator of the Wnt
pathway and mutations in this gene often initiate the formation of CRC, as loss of APC
occurs early on in carcinogenesis for sporadic and hereditary familial adenomatous
polyposis (FAP) tumours (Ashton-Rickardt et al., 1989; Groden et al., 1991; Kinzler et al.,
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1991). Moreover, it was found that mutations that result in activated Wnt signaling occur
in about 80% of sporadic CRCs (Powell et al., 1992). Ultimately, loss of APC function
prevents phosphorylation and degradation of β-Catenin (Miyaki et al., 1994). This leads to
the accumulation and subsequent translocation of β-Catenin to the nucleus, driving
uncontrolled LEF/TCF-mediated gene transcription (Polakis, 1999). As outlined in section
1.1.4, target genes of LEF/TCF transcription are associated with the “stem cell signature”
and enhance cell proliferation, migration and adhesion processes (Sansom et al., 2004;
Gregorieff and Clevers, 2005; Van der Flier et al., 2007). Therefore, activation of Wnt
signaling drives tumorigenic processes.
1.2.4

Mouse models of colorectal cancer

Mouse models addressing different CRC subtypes have been developed over several
decades to closely approximate the molecular, histopathological, and etiological
characteristics observed in human CRC. Moreover, many of the molecular interactions and
signaling strategies in the Wnt pathway are highly conserved between humans and mice
enhancing mouse models as faithful models of human CRC.

Mouse models of FAP
The APCmin mouse model was first reported in 1990 as a model of FAP after a mouse
with multiple intestinal neoplasia was discovered from an ethyl-N-nitrosourea chemical
mutagenesis screen (Moser et al. 1990). Sequencing of this mouse, revealed it carried a
truncation mutation of one allele of APC (Moser et al. 1990). Therefore, the mouse line
was termed APCmin (multiple intestinal neoplasia). Interestingly, one allele of the APC
gene remains intact and capable of maintaining a functional β-catenin destruction complex
to prevent tumourigenesis. However, sporadic loss of the functional allele over time leads
to the activation of β-catenin and expression of Wnt target genes. The most common cause
of loss of heterozygosity of APC is mitotic nondisjunction of chromosome 18 where the
APC gene is located (Dalton et al., 2007; Powell et al., 1992).

The APCmin model recapitulates many aspects of FAP. Tumourigenesis in this model is
driven by truncation mutations in the APC gene. APCmin tumours also share

25

histopathological characteristics with early human CRC (Zasadil et al., 2016). However,
there are slight discrepancies between human FAP and the APCmin mouse model. Firstly,
APCmin mice primarily develop tumours in the small intestine, in contrast to humans
where polyps are primarily observed in the colon (Cunningham et al., 2010; Kettunen et
al., 2003). The reasons for this are not fully understood. Secondly, it is not uncommon to
see hundreds of tumours lining the colonic epithelium in human FAP (Cunningham et al.,
2010). However, APCmin model shows approximately 30 polyps in the ileum of the small
intestine (Moser et al. 1990). Over time, human FAP tumours may metastasize, however,
this phenomenon is rarely observed in APCmin mice. APCmin tumours may occasionally
invade the underlying mucosa and muscularis externa but they do not metastasize. A
possible explanation for this may be the relatively short lifespan of these mice (30 weeks),
which does not allow sufficient time for more advanced stages of the disease to develop.
Despite this, the APCmin mouse model is one of the most commonly used mouse models
of CRC.

Cre-lox mouse models of CRC
Although the APCmin model is useful for studying intestinal tumourigenesis, it has limited
utility when investigating the earliest stages of CRC. Initial onset of CRC is caused by
inactivation of both alleles of APC, while in the APCmin mouse model, the time that
heterozygosity is lost is unknown (Gryfe et al. 1997). Therefore, a model in which both
alleles of APC could be deleted at specific time points was created using a conditional CreloxP recombination system (Evans et al., 2016). The Cre-loxP system recombines DNA
between any two loxP sites in the same orientation when Cre-recombinase is expressed by
a tissue-specific promoter (Evans et al., 2016). For example, to direct conditional APC loss
in a K19-expressing cell, tamoxifen mediated cre-expression would be directed from a
tissue specific promoter K19 to an essential exon (exon 14) of APC flanked by loxP sites.
As the K19-CreERT transgene encodes a cre-recombinase estrogen-receptor (ER) linked
protein, it will remain inactive until tamoxifen is present and binds to the ER, freeing the
Cre-recombinase and activating the enzyme to cut the loxP sites surrounding exon 14 of
APC. This results in loss of functional APC protein in K19 expressing cells and
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subsequently tissue specific/conditional knockout of APC with tamoxifen induction. An
advantage to using this model is the ability to drive expression of Cre-recombinase from
different tissue-specific promoters, thereby driving recombination of a number of genes in
different tissues or cellular compartments. Accordingly, this model has enabled the initial
stages of intestinal tumorigenesis to be studied in detail. In particular, this model was used
to identify Lgr5 as a cellular origin of CRC, as mentioned in section 1.2.2.

Besides altering the function of genes in a specific tissue or cell compartment, Cre-Lox
technology has enabled cell lineage tracing to determine the genetic origin of a tumour. For
example, LacZ reporter gene crossed to a K19-Cre mouse will express B-galactosidase
when recombined (Asfaha et al., 2015). Additionally, daughter cells of the recombined
cells will inherit the genetic marker, which can then be stained using X-gal. This allows
for visualization of K19 cells and progeny when crossed to a tumour model. This model
was used to identify K19 as a cellular origin of CRC, as detailed in section 1.2.2.
Furthermore, the same principle of genetic lineage tracing has also been used in the nonmutated intestine to identify ISCs as described in section 1.1.3.

Mouse models of colitis-associated CRC
The AOM/DSS model is a well-established animal model of colitis-associated cancer,
whereby colorectal cancer is induced chemically. In this model, a single intraperitoneal
(i.p.) injection of a genotoxic colonic carcinogen, azoxymethane (AOM) (10 mg/kg body
weight) and exposure to a non-genotoxic inflammatory agent, dextran sodium sulfate
(DSS) (2.5%) in the drinking water for five days results in the development of multiple
colonic tumours in approximately 9-12 weeks, with mice becoming moribund at 20 weeks
with an average of 7 tumours (Rosenberg, 2008). DSS is toxic to the epithelial lining of the
colon and produces severe colitis similar to what is seen in patients with inflammatory
bowel disease (IBD) (Rosenberg, 2008). The pathogenesis of tumours induced in mice
exposed to AOM/DSS is similar to that observed in human colitis-associated cancer. For
instance, tumours are frequently found in the distal part of the colon, which is also the
predominant location of colitis-associated cancer in humans (Rosenberg, 2008). Likewise,
AOM/DSS tumours have been reported to share molecular features with human CRC, such
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as dysregulation of β-catenin-signaling pathway (Takahashi et al., 1998; Takahashi et al.,
2000) and mutations in K-Ras (Takahashi and Wakabayashi, 2004). However, they rarely
display mutations in p53 or Smad4 and detailed molecular mechanisms of the AOM/DSS
model are still very limited (Rosenberg, 2008). Regardless, the AOM/DSS model is
representative of the colitis-associated colorectal cancer observed in humans.
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1.3 Cancer Stem Cells
The cellular composition of CRCs maintains a high degree of similarity to normal intestinal
tissue, with the appearance of glandular structures, although structurally disorganized in
comparison to normal tissue (Medema and Vermeulen, 2011). Moreover, a variety of
differentiated cell types are found in CRCs that are also present in the normal intestinal
tissue (Blank et al., 1994; Grabowski et al., 2004; Marsh et al., 1993; Pierce et al., 1977;
West et al., 1988). These findings can also be interpreted to suggest that like their normal
tissue of origin, tumour cells are organized into a hierarchy of potency. Support for this
interpretation was enforced by the discovery of stem cell-like cancer cells that expressed
ISC markers (see section 1.1.3), which were multipotent and capable of self-renewal
(Ricci-Vitiani et al., 1988; O’Brien et al., 2007; Dalebra et al., 2011). These findings
support the cancer stem cell (CSC) hypothesis, which posits only a small subpopulation of
cancer cells are capable of driving tumour growth and progression. Furthermore, it is
postulated that therapy-resistant CRC arises from CSCs capable of evading treatment and
persisting in tumours to cause relapse (Sarkar et al., 2009; Yu et al., 2012). Therefore,
CSCs represent a novel therapeutic target for the treatment and/or prevention of tumour
progression. However, there are still many uncertainties regarding their identification,
functional properties and importance, which are outlined below (Medema, 2013).
1.3.1
History and Identification
CSCs were first identified nearly 20 years ago in acute myeloid leukemia through serial
transplantation assays (Lapidor et al., 1994). In this assay, subpopulations of tumour cells
expressing identified surface markers are sorted via FACS, transplanted into
immunocompromised mice and evaluated for tumour formation (Figure 9). Using this
experimental technique, Bonnet & colleagues were able to identify a small subpopulation
of CD34+/CD38- leukemic cells capable of establishing human leukemia (Bonnet et al.,
1997). Interestingly, the other cell populations failed to form tumours. These results
indicated that CD34+/CD38- cell population labelled cancer initiating cells or CSCs
(Bonnet et al., 1997). Accordingly, serial transplantation assays using xenografts have
become the gold standard to define CSCs, and many CSCs have been identified in several
solid tumour types including: medulloblastoma/glioblastoma (Singh et al., 2004), breast
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(Al-Hajj et al., 2003), pancreatic (Fredebohm et al., 2012), prostate (Collins et al., 2005),
and colorectal (Ricci-Vitiani et al., 2007; O’Brien et al., 2007) cancers, among many
others. However, there are many limitations with this assay when applied to epithelial
cancers, such as colorectal cancers (Nguyen et al., 2012; Zeuner et al., 2014; Plaks et al.,
2015). This assay has identified the existence of CSCs in CRC but these cells often show
poor engraftment, even after enrichment for CSC markers (Ricci-Vitiani et al., 2012;
O’brien et al., 2007; Kobayashi et al., 2012; Kemper et al., 2012). This may largely be due
to sorted epithelial cells undergoing anoikis during detachment from the tissue (Fuji et al.,
2017). Moreover, epithelial stem cells are passively regulated by their microenvironment
(niche), suggesting that repopulation efficiency may reflect the robustness or fitness of the
transplanted cells into the recipient niche rather than stemness (Fuji et al., 2017).
Interestingly, this phenomenon was observed in serial transplantation assays performed
with melanoma cells. Quintana et al. found that the tumorigenic capacity of transplanted
melanoma cells changed with the level of immune deficiency of host animals (Quintana et
al. 2008).
To circumvent the drawbacks of serial transplantation assays, lineage tracing of genetically
marked cells has been used to identify colorectal CSCs in genetically traceable mouse
tumour models (Driessens et al., 2012; Schepers et al., 2011; Asfaha et al., 2015). The first
evidence to support the existence of CSCs using this method, was demonstrated in three
independent lineage tracing studies of brain (Chen Li et al., 2012), skin (Driessens et al.,
2012) and intestinal (Schepers et al., 2011) cancers. In regards to colorectal cancer,
Schepers et al. employed the confetti mouse model to initiate “lineage retracing” in
intestinal adenomas. They demonstrated that a small subpopulation (5-10%) of tumour
cells was labelled by the ISC marker Lgr5 which fueled the growth of established intestinal
adenomas and displayed multi-lineage differentiation potential indicative of CSC activity.
However, it is important to note that sorted Lgr5+ intestinal tumour cells have not been
shown to form tumours using the traditional method of serial transplantation assays.
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Figure 9 | Identification of cancer stem cells. Serial transplantation assays allow for the
identification of cancer stem cell populations. Patient tumours are dissociated into single
cell populations and injected into immunocompromised mice to assess the formation of
tumours. Only the injection of CSCs will yield tumours, whereas injection of tumour cells
that lack cancer stem cell properties will not result in tumour formation or growth. To
determine whether the cancer stem cell population is capable of self-renewal, xenografted
tumours are removed and put through this process again to assess tumour formation/growth
in secondary recipients. Only the cancer stem cell population will possess long-term selfrenewal capacity and it will regenerate the tumour, whereas injection of non-CSCs will not
re-initiate tumour growth.
1.3.2

Colorectal cancer stem cell markers

Identification of colorectal CSCs relies heavily on the expression of cell surface or ISC
markers. As such, many CSC markers have been proposed and their ability to robustly
identify the colorectal CSC population is discussed below.
1.3.3

Cell surface markers

A number of cell surface markers have been proposed to identify colorectal CSCs including
CD133 (Ricci-Vitiani et al., 2007; O’Brien et al., 2007), CD44 (Chu et al., 2009) and
ALDH1 (Huang et al., 2009). Using serial transplantation assays, these markers were
identified on the basis that enriched populations initiate tumours in xenograft models,
whereas depleted populations did not. However, many of the CSC markers identified from
these assays were chosen because the proteins were expressed in colorectal cancer tumours.
Unlike this reasoning, the original studies conducted on leukemic CSCs relied heavily on
the understanding of stem-progenitor hierarchies in the healthy bone marrow to establish
relevant highly reliable CSC markers (Lapidot et al., 1994; Bonnet et al. 1997). However,
few studies have employed this methodology. In fact, one study implicated CD44 as a CSC
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in breast cancer despite the lack of CD44 in normal breast epithelial stem-progenitor
hierarchies (Al-Hajj et al., 2003). This suggests that CD44 was incorrectly chosen for its
differential expression in breast tumours. In addition to CD44, CD133 or prominin 1 has
been suggested as a CSC marker in a variety of cancers, which shares expression with its
normal stem-progenitor tissue counterparts. Although recently, it was revealed that CD133
is widely expressed in many tissues (Shmelkov et al., 2008). Therefore, there is
considerable disagreement over the validity and usefulness of this CSC marker. Initially,
CD133 was proposed as a useful CSC marker in CRC (O’Brien et al., 2007; Ricci-Vitiani
et al., 2007), as well as brain cancers (Singh et al., 2004; Bao et al., 2006). However, these
findings were later refuted in subsequent studies (Dalebra et al., 2007; Shmelkov et al.,
2008; Joo et al., 2008; Ogden et al., 2008; Wang et al., 2010; Chen et al. 2010). These
studies highlight the need for selection of CSCs that are relevant and specific to the
underlying stem cell biology of normal tissues from which the cancer originates.
The following sections outline a select few cell surface proteins that may function as CSC
markers in CRC.
CD133
CD133 or prominin-1 expression has been used to identify CSCs in a number of different
cancers including medulloblastoma/glioblastoma (Singh et al., 2004), prostate (Collins et
al., 2005; Richardson et al., 2004), pancreatic (Hermann et al., 2007) and colorectal cancers
(Ricci-Vitiani et al., 2007; O’Brien et al., 2007). CD133 is a 120kDa five-transmembrane
cell surface protein that has been reported to affect many cellular processes including
stemness, tumourigenesis, chemo/radioresistance, metabolism, autophagy and apoptosis
(Li, 2013). In the colon, CD133 was the first CSC marker used. It was found that 10003000 CD133+ cells were capable of initiating tumours in immunodeficient mice (RicciVitiani et al. 2007; O’Brien et al. 2007). However, recent studies have suggested that
CD133 may not be a robust CSC marker. Importantly, it was found that when the CD133
negative population was transplanted into NOD/SCID mice, tumour formation was
initiated (Shmelkov et al. 2008). Moreover, knockdown of CD133 does not affect colony
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formation efficiency or tumorigenic capacity, highlighting the need for a more pertinent
CSC marker in CRC (Du et al., 2008).
CD44
Another commonly employed CSC marker is CD44. CD44 has been identified as a CSC
marker in breast (Al-Hajj et al., 2003; Pham et al., 2011), prostate (Collins et al., 2005),
gastric (Yoon et al., 2014) and colorectal (Du et al., 2008; Dalebra et al., 2007) cancer.
Functionally, CD44 is a receptor for hyaluronic acid and plays a role in normal cell-cell
adhesion as well as proliferation, motility, adhesion and cell survival in cancer (Keysar and
Jimeno, 2010; Afify et al., 2009; Marharba and Zoeller, 2004). In comparison to normal
tissue, CD44 has been found to be upregulated in colorectal cancer tissue. Moreover,
CD44+ cells isolated from primary colorectal tumours demonstrate increased tumorigenic
capacity, with as few as 100 CD44+ cells leading to tumour initiation in mice (Du et al.,
2008; Dalebra et al., 2007). In contrast to CD133, CD44+ cells demonstrate enhanced
colony formation efficiency indicating self-renewal (Chu et al., 2009; Du et al. 2008; Wang
et al., 2012). Furthermore, CD44+ cells formed heterogeneous tumours containing CD44cells in vivo, demonstrating the ability of this population to differentiate into other cancer
cell types (Chu et al., 2009). Importantly, when CD44 was knocked down in primary
tumour samples, colony formation and tumourigencity was inhibited. Thus, highlighting
the role of CD44 as a functional marker of colorectal CSCs.
ALDH1
In addition to CD133 and CD44, aldehyde dehydrogenase 1 (ALDH1) is a commonly used
marker of CSCs. It has been detected in numerous cancers including ovarian (Deng et al.,
2010), bladder (Su et al., 2010) and colorectal (Huang et al., 2009). Functionally, ALDH1
is a member of the ALDH gene family, which catalyzes the oxidation of acetaldehydes and
retinal (retinaldehyde) (Tomita et al., 2016), and it contributes to a variety of cellular
processes through activation of retinoid signaling. The expression of ALDH1 is detectable
by antibody based methods or enzymatic assay. However, the enzymatic assay lacks
specificity for different ALDH isoforms. The activity of ALDH1 is elevated in normal
stem/progenitor cells including ISCs (Dalebra et al., 2007). In several studies, when cancer
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cells were sorted based on ALDH1 activity, a tumour initiating population was revealed
(Tanei et al., 2009; Su et a.l, 2010; Kim et al., 2011; Sullivan et al., 2010). These results
suggest that high activity or expression of ALDH1 is a useful method for identifying and
isolating CSC populations in a variety of cancer types (Tanei et al., 2009; Su et al., 2010;
Kim et al., 2011;Huang et al., 2009).
Known intestinal stem cell markers
Lgr5
In 2012, Clevers et al. provided the first in vivo validation of a colorectal CSCs using a
novel transgenic mouse model, which allowed them to visualize lineage re-tracing in
established tumours (Schepers et al., 2011). This work stemmed from earlier genetic fate
mapping studies in the normal intestine. In this study, they identified Lgr5-expressing crypt
base columnar cells as a stem cell population able to give rise to all intestinal cell types
(Barker et al., 2007). Interestingly, upon ablation of Lgr5+ cells in the normal intestine,
other stem cells have been shown to regenerate Lgr5+ cells and their progeny (Tian et al.,
2011). This demonstrates the presence of a heterogeneous pool of stem cell populations in
the normal intestinal epithelium. Though it is not known whether CSCs represent a
heterogeneous pool encompassing different cell types in a much like the normal intestinal
epithelium.
Proposed intestinal stem cell markers
K19
Our laboratory recently identified Keratin-19 (K19) as a potential CSC marker.
Cytokeratins are a multigene family of intermediate filaments, critical in the maintenance
of the cytoskeleton but expressed in different lineages in the epithelium (Moll et al., 1982).
Keratin-19 is the smallest known acid keratin (approximately 40kDa) and is epithelialspecific, found in a broad range of epithelial tissues (Lapouge et al., 2011). In the small
intestine and colon, our laboratory identified K19+ cells as radioresistant tissue stem cells
capable of giving rise to Lgr5+ cells (Asfaha et al., 2015). Interestingly, K19 is also
amplified in many solid tumours making it an ideal candidate marker for CSCs (Lapouge
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et al., 2011). Our preliminary data (not included here) further demonstrated that K19
identifies CSCs in established colonic tumours.
1.3.4

Targeting cancer stem cells

CSCs are believed to play an important role in the maintenance of tumour growth,
metastasis, as well as therapy resistance. Therefore, from a therapeutic standpoint, the
elimination of CSCs is necessary to eliminate the tumours. However, treatments that are
currently used in CRC are aimed at targeting rapidly dividing cells that make up the bulk
of the tumour via chemotherapy or radiation. Unfortunately, these treatments are often
unsuccessful at targeting slow-cycling CSCs. As a result, CSCs are thought to evade
treatment, causing relapse of disease and the emergence of therapy-resistant CRC (Figure
10). This notion, has led to multiple studies targeting CSCs in CRC. Recently, Shimokawa
et al and de Sousa e Melo et al investigated targeted ablation of Lgr5 expressing CSCs in
two different models of colorectal cancer. Initially, both groups observed tumour
regression, as one would expect to see if the source of cancer growth is being ablated.
However, upon discontinuing ablation of Lgr5+ cells in established tumours, Lgr5+ cells
reappeared and growth rapidly resumed (de Sousa e Melo et al., 2017; Shimokawa et al.,
2017). Moreover, targeted ablation of Lgr5+ cells using an antibody-directed
chemotherapeutic in APCmin mouse model had no effect on tumour burden (Juntila et al.,
2015). This demonstrates that depending on the tumour model, the CSC pool might
encompass different cell phenotypes and that elimination of Lgr5+ CSCs might alter
tumour growth but may not eradicate the disease. This highlights the need to identify other
CSC populations that may exist in CRCs.
From what we know about the functional role of CSCs in CRC, it is evident that a method
of targeting CSCs is necessary to eradicate disease. However, this presents a number of
difficulties related to the stem cell niche and bona fide markers. It is likely that the tumour
environment regulates CSCs, much like what is observed in the normal intestinal
environment. However, it remains unknown whether the tumour initiating activity is
inherent to CSCs. This has major implications in terms of targeting CSCs. If the latter is
correct, simply ablating CSCs will likely have non-significant effect on tumour growth
other stem cells in the environment may assume the role of CSCs. Secondly, a major
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challenge in targeting CSCs remains the lack our understanding of definitive markers
identifying CSCs. The markers that have been used to identify CSCs thus far are poor
candidates for antibody-directed therapy, as they are broadly expressed in healthy tissue.
Together these challenges highlight the need to increase our understanding of normal ISCs
and CSCs, as well as the seemingly interconnected relationship between niche
environments and CSC plasticity to develop effective therapeutic targets.

Figure 10 | CSC-targeted therapy versus traditional cancer therapy. This figure was
originally published online in Sigma-Aldrich. Cancer stem cells: new targets for cancer
therapy [https://www.sigmaaldrich.com/technical-documents/articles/biofiles/the-cancerstem-cell.html]. Modified figure is being reproduced for educational purposes only and not
for any commercial use. Figure is included in the M.Sc. dissertation with attribution.
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1.4

Rationale

Evidence in the normal intestinal epithelium reveals stem cell populations represent a
heterogeneous pool encompassing different cell types in a dynamic equilibrium (Barker et
al., 2007). For example, stem cell activity is observed at the base of intestinal crypts in
rapidly dividing cells that express leucine-rich repeat-containing G protein-coupled
receptor (Lgr5) (Tian et al., 2011). However, genetic ablation of Lgr5+ cells in vivo does
not appear to drastically alter tissue homeostasis, suggesting that their loss can be
compensated for by the recruitment of a different Lgr5 negative stem cell populations
which are capable of regenerating Lgr5+ cells (Ricci-Vitiani et al., 2007; O’Brien et al.,
2007; Rizk et al., 2012; Moll et al., 1982). Our laboratory has identified Keratin-19 (K19)
expressing cells as tissue stem cells at the apex of cellular hierarchy able to give rise to
Lgr5+ cells (O’Brien et al., 2007). However, the extent to which these processes are
paralleled in malignant tissues through CSC activity remains unclear. In 2012, Clevers and
colleagues identified Lgr5 as a marker of colorectal CSC using a model of lineage retracing in established tumours (Ricci-Vitiani et al., 2007). Based on the results and
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implications of these studies, I aim to determine if K19 labels a cancer stem cell population
in an in vivo model of colorectal cancer.
1.4.1

Hypothesis

I hypothesize that K19 will label a cancer stem cell population that is distinct from
previously identified Lgr5+ cancer stem cells and contributes to colorectal tumour growth.
1.4.2

Objectives

1. Determine if K19 labels a cancer stem cell population in colorectal cancer
2. Assess the effects of Lgr5+ ablation on tumour growth, both in vivo and in vitro.
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Chapter 2
MATERIALS AND METHODS
2.1

Experimental Animals

All animal care and experimental procedures were approved by the Canadian Council of
Animal Care and the Animal Use Subcommittee of the University of Western Ontario.

2.1.1

Animal husbandry

Mice were housed in transparent plastic cages in a room with a 12h light/12 h dark cycle.
The mice were fed standard laboratory chow (Lab Diet) and tap water ad libitum.
2.1.2

Breeding

All strains were generated on a C57BL/6 background. Mice were bred at approximately 6
weeks of age. Pups were weaned at approximately 4 weeks old when feeding
independently. Pups were sexed and separated at weaning, and ear-tagged for
identification. At this time, small tail biopsies (3-4 mm) were collected for genotyping.
2.1.3

Genetic mouse models

A number of transgenic mouse models were utilized in this study (Table 1). The transgenes
used contained exons of the gene of interest flanked with loxP sites, or insertion of human
diphtheria toxin receptor to enable conditional deletion of genes, or cre-recombinasedriven by a tissue specific promoter to induce lineage tracing.
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Table 1| Transgenic mouse models
Model

Type of
transgene

Expression

Mutation

Effect

Reference

K19CreERT2

BAC

Inducible

Tamoxifen inducible CreERT2 fusion
gene inserted into K19 gene coding
region of K19 containing BAC clone
(BAC RP-23-24N13).

Label K19+ expressing cells and progeny (Asfaha et
when combined with a reporter gene under al., 2015)
control of the Rosa 26 locus.

Rosa26TdTomato

Knock-in

Inducible

Cre reporter allele with loxP flanked Spatiotemporally label cells and progeny (Luche et
stop cassette preventing transcription red when crossed to a cre recombinase gene al., 2007)
of
CAG
promoter-driven
red under the control of a promoter of interest
fluorescent protein variant (TdTomato)
inserted into the Rosa 26 locus.

Lgr5-DTReGFP

Knock-in

Constitutive Exon 1 in the Lgr5 gene is linked in Expression of eGFP functions as a reporter (Tian et al.,
frame to eGFP and a human DTR for Lgr5 expression and diphtheria toxin 2011)
cDNA, producing a fusion protein
receptor
confers
diphtheria
toxin
sensitivity to Lgr5+ expressing crypt base
columnar cells.
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APCf/f

Knock-in

Inducible

Exon 14 in the APC gene is flanked by Ablation of APC functional protein when (Colnot et
loxP sites
crossed to mice a cre recombinase gene al., 2004)
under the control of a promoter of interest

APCmin

Chemically
induced
mutation

Constitutive Germline nonsense mutation at codon Spontaneous loss of heterozygosity leads (Moser et
850 of APC
to tumour formation in small intestine and al., 1990)
colon in ~6 months
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2.1.4

Mouse lines

To address the aims of this thesis, a number of mouse lines were generated from the mouse
models outlined in Table 1. The mouse lines generated were used to visualize progeny of
K19 and ablate Lgr5 cells in various CRC models. The details of these mouse lines are
outlined in Table 2.
Table 2 | Mouse lines
Mouse line

Effect

K19-CreERT;Rosa26-TdTomato

Treatment with tamoxifen induces excision of the
STOP codon preventing TdTomato expression in
K19 expressing cells resulting in robust TdTomato
fluorescence. When these mice are treated with
AOM/DSS, this allows for lineage tracing of K19+
cells and progeny in tumours.

K19-CreERT;Rosa26TdTomato;APCmin

When crossed to APCmin mice which
spontaneously form tumours, we are able to
lineage trace K19 cells in tumours using a similar
principle to the above mouse line.

Lgr5-DTR-eGFP

When these mice are treated with AOM/DSS, this
mouse model allows for specific ablation of all
Lgr5+ cells in tumours.

Lgr5-DTR-eGFP; K19-CreERT;APCf/f

Treatment with tamoxifen induces a loss of
functional APC protein in K19 expressing cells,
resulting in tumour formation. Additionally, with
the presence of Lgr5-DTR, this allows for specific
ablation of all Lgr5+ cells in K19 APCf/f derived
tumours.
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K19-CreERT2;APCf/f

2.1.5

Treatment with tamoxifen induces a loss of
functional APC protein in K19 expressing cells,
resulting in tumour formation.

Experimental design

K19-CreERT;R26TdTomato;APCmin
To induce cre-mediated lineage tracing of TdTomato in established adenomas, 3mg of
tamoxifen in 200 μL corn oil was administered to 20 week-old mice by oral gavage (Figure
11). Following tamoxifen induction of Cre recombinase in K19+ cells, TdTomato labelling
was assessed by immunofluorescence microscopy. Mice were sacrificed at 24 hours, 10
days and 4 weeks post-tamoxifen. Tissue sections were counterstained with DAPI (Fisher).

Figure 11 | Experimental protocol for K19-CreERT2;R26TdTom;APCmin mice
K19-CreERT;R26TdTomato
To assess CSC properties of K19+ cells in vivo, I performed lineage tracing analysis of
adenomas K19-CreERT;R26TdTomato mice treated with AOM/DSS mice. To induce cremediated lineage tracing of TdTomato in established adenomas, 3mg tamoxifen (K19) in
200 μL corn oil was administered to 15-week old mice by oral gavage (Figure 12).
Following tamoxifen induction of Cre recombinase in K19+cells, TdTomato labelling was
assessed as described above.
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Figure 12 | Experimental protocol for K19-CreERT2;R26TdTom AOM/DSS mice
Lgr5-DTR-eGFP AOM/DSS
To examine the effect of Lgr5+ cancer stem cell ablation on tumour initiation and growth
in vivo, I administered 500ng of diphtheria toxin 2x per week from week 3 post-AOM
(Sigma) until the experimental endpoint at 20 weeks, to selectively ablate Lgr5+ cells in
Lgr5-DTR-eGFP mice treated with AOM/DSS (Figure 13). Administration of DT (Sigma)
from week 3 onwards ensured Lgr5+ cells are ablated for the duration of tumour initiation
and growth. Therefore, cohorts of experimental (DT-treated) and control (saline- treated)
mice (n > 10 per group) were compared with respect to tumour burden (number and size)
and histology at 20 weeks.

Figure 13 | Experimental protocol for Lgr5-DTR-eGFP AOM/DSS mice

2.2 Genotyping of mice
Polymerase chain reaction (PCR) was performed to genotype weaned mice using genomic
DNA (gDNA) extracted from tail biopsy. Confirmatory genotyping was also performed at
the time of death to ensure the mouse was assigned to the correct experimental cohort.

44

2.2.1

Nucleic acid isolation

Tail samples were placed in 1.5 mL centrifuge tube and stored at 4°C until use. 75 L of
tail lysis buffer (Appendix II) was added to tubes and incubated at 98°C for one hour.
Samples were cooled on ice for 5 minutes and 75 L of neutralization buffer was added
(Appendix II). Following neutralization, samples were centrifuged at 4000 rpm for 3
minutes at 4°C and the supernatant was used for PCR. gDNA was stored at room
temperature (RT) for short term use and at 4°C for long term storage.
2.2.2

PCR protocol

PCR was carried out in thin-wall 12-well strip tubes (Fisher). Two L of gDNA, extracted
as described above, was added to each tube with 18 L of PCR mix (described in Table 3)
containing the DNA polymerase (FroggaBio), H2O (FroggaBio), and gene-specific
primers. One negative control (H2O only) and positive control tube was run with every
PCR reaction. Primers were used as described from previous publications (Appendix III).
The caps were placed firmly on tubes and the PCR reactions were on a thermocycler (Life
Technologies, Verti PCR machine). PCR conditions and primers are listed in Appendix IV.
Table 3 | Constituents of PCR mix
Component
Taq polymerase (FroggaBio)

20 L reaction
10 L

Forward primer

0.5 L

Reverse primer

0.5 L

Template DNA

2 L

Nuclease-free H2O (FroggaBio)

7 L

2.2.3
Visualization of PCR products
PCR products were visualized by gel electrophoresis. Agarose gels were made by
dissolving 8 g of agarose (Fisher) in 400 mL TAE buffer [40mM Tris; 19mM Acetic Acid
(Fisher)] in a conical flask by heating in a microwave until boiling. Ten L of ethidium
bromide (Sigma) was added to the melted gel and agitated carefully to ensure even
distribution without incorporating air bubbles into the gel. One hundred fifty mL of gel
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solution was poured into each mold (Bio-Rad) and combs inserted to create wells. Once
the gels were set, the combs were removed and they were placed into gel electrophoresis
tanks and covered with TAE.

Ten µL PCR product was added to each well of the agarose gel and run alongside a
molecular weight ladder (Fisher). The gel was run at 140 V for approximately 30 minutes,
and visualized using a GelDoc UV trans illuminator (Bio-Rad).

2.3

AOM/DSS Administration

To induce colonic tumours, K19-CreERT/R26TdTomato, Lgr5-DTR-eGFP and WT mice
were subjected to a well-established, chemically-induced inflammation protocol (Wirtz et
al., 2007; Tanaka, 2003). Mice (6-8 weeks old) were injected intraperitoneally (i.p.) with a
single dose of AOM (with 10 mg/kg, (Sigma)) diluted in saline. After one week, 2.5% DSS
(Gojira) was administered in the drinking water for 5 days, followed by regular drinking
water. Throughout DSS administration, mice were assessed for health condition by using
a scoring system. Mice were euthanized if endpoints were reached or 16-20 weeks post
AOM administration.

2.4

Tamoxifen Preparation and Administration

Tamoxifen (Sigma) was dissolved in corn oil (Sigma) to a final concentration of 20 mg/mL.
The sample was placed in a rotor and heated at 37°C until the tamoxifen was completely
dissolved. In order to induce Cre expression in Cre-ERT mice, tamoxifen was administered
via oral gavage. For tamoxifen dosing of each mouse line, please refer to Table 4.

Table 4 | Doses of tamoxifen used for each mouse line
Mouse Line Dose of Tamoxifen
APCmin/K19-CreERT/Rosa26-tdTomato

3mg

K19-CreERT/Rosa26-tdTomato

3mg

Lgr5-DTR-eGFP/K19/APCf/f/Rosa26-tdTomato

6mg

K19-CreERT/APCf/f/Rosa26-tdTomato

6mg
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2.5

Diphtheria Toxin Preparation and Administration

Diphtheria toxin stock solution was prepared from 1 mg of solid powder (Sigma). The
powder was first dissolved in 1 mL of 0.9% saline. The solution was then diluted to a final
concentration of 500 ng/200 µL and transferred to centrifuge tubes. Final prepared toxin
solution was stored at -80°C and thawed directly before application.

2.6
2.6.1

Tissue Preparation
Tissue dissection

Mice were euthanized in a CO2 chamber for 4-5 minutes, followed by cervical dislocation.
Mice were sprayed with 70% ethanol and the skin and muscle of the abdomen cut through
to open the abdominal cavity. The small intestine and colon were removed and flushed
with PBS (Fisher). For organoid culture studies, 5-10 cm of the proximal small intestine
and the entire colon was collected. For lineage tracing in AOM/DSS experiments only, the
colon was collected. For APCmin lineage tracing experiments, both the small intestine and
colon were collected. For Lgr5-DTR AOM/DSS experiments, small intestine and colon
were collected. All tissues were collected into 4% paraformaldehyde (PFA; Santa Cruz) on
ice.
2.6.2
Tissue fixation
For histological analysis, the organs were cut longitudinally, “Swiss rolled” (Moolenbeek
and Ruitenberg 1981), inserted into embedding cassettes and fixed 6-8 hours in 4%
paraformaldehyde in PBS at 4°C.
2.6.3

Preparation of tissues

Tissues were cryopreserved in 30% sucrose in PBS at 4°C for 48 hours. For subsequent
histological analysis, tissues were embedded in Optimal Cutting Temperature (OCT)
(Fisher) and stored at -80°C overnight before being cut to 5 µm slices with a microtomecryostat (Leica) at -21°C and picked up on glass slides (Fisher). Slides were stored at 20°C. For all imaging studies, 4 serial sections of tissues were collected for analysis.
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For long-term cohorts where an accurate tumour count was required, small and large
intestines were flushed with cold 1 X PBS and opened longitudinally on filter paper
(Fisher). Tumour number and volume (calculated as length x width x width) counts were
performed and the gut was rolled using dissection tweezers and placed into cassettes and
fixed as described above.

2.7
2.7.1

Histology
Hematoxylin & Eosin (H&E) staining

For routine histological analysis, frozen slides were warmed to room temperature for 10
minutes and rehydrated for two minutes in descending gradient of ethanol (100%, 95%,
70% and 50%). The tissue slides were washed in ddH2O and stained for 7 minutes in a
ready to use hematoxylin solution (Cedarlane). Residual stain was washed off in tap water.
In order to stain eosinophilic structures and the cytoplasm, slides were stained for 10 s in a
1.5% eosin (Fisher) solution. Residual staining solution was washed off in distilled water.
The tissue was dehydrated in ascending ethanol gradient (50%, 70%, 95%, and 100%) and
then incubated in xylenes (Fisher) for 5 min. The tissue slides were air-dried and mounted
using toluene-based mounting medium (Fisher).
2.7.2

Nuclear counterstaining for immunofluorescence microscopy

Slides were washed with PBS for 5 minutes twice, incubated in 0.25% Triton X-100
(Fisher) in PBS for 10 minutes, rinsed in PBS for 5 minutes, and then counterstained with
1:1000 DAPI (Fisher). Slides were preserved in water-based mounting medium
(Vectashield) and covered with a glass coverslip (Fisher).
2.7.3

Image acquisition & analysis of slides

Prepared slides were observed using EVOS FL Auto microscope (Life Technologies).
DAPI UV (357-447 nm) filter was used to observe nuclei (blue), and RFP (red) were
visualized under the 530-595 and 470-510 nm excitation filters, respectively. The
percentage of lineage tracing was quantified using ImageJ. The area of lineage tracing or
tumors was determined by outlining areas on ImageJ using the freehand area outlining tool.
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Raw values were transferred to excel, and the percentage of lineage tracing was determined
with the following formula ([total area of lineage tracing in tumours/total area of tumour]
x 100).

2.8

Organoid Culture

The methods outlined below for intestinal organoid culture were modified from the
methods originally presented by Sato et al., to increase efficiency (Sato et al., 2009).
2.8.1
Experimental protocol
Eight-week old Lgr5-DTR-eGFP;K19-CreERT;APCf/f and K19-CreERT;APCf/f mice
were treated with 6 mg of tamoxifen via oral gavage. Two days post-tamoxifen treatment,
small intestine and colonic tissues were cultured. R-spondin was removed from the media
at day 5 to select for APCf/f organoids (normal organoids with intact APC require Rspondin for survival, while APCf/f organoids do not). Organoids were passaged and treated
with 20 ng/mL DT or vehicle (0.9% saline) from day 10 until day 30. At day 20, a subset
of organoids had DT removed from the media (Figure 14). All experiments were repeated
in triplicate.

Figure 14 | Experimental protocol for in vitro Lgr5 ablation experiments.

2.8.2

Isolation of intestinal crypts

Fifteen cm of small intestine was flushed with PBS (Fisher). The intestine was then opened
longitudinally and scraped firmly using a glass cover slip to remove the villi. Once scraped,
the intestine was transferred to a centrifuge tube and washed vigorously with PBS. The
intestine was resuspended in 10 mL of 2.5 mM EDTA (Fisher) in PBS and incubated at
4°C in a rotator for one hour. The intestine was removed from solution and cut into 0.5 mm
pieces and resuspended in 10 mL fetal bovine serum (FBS; Fisher) in PBS. To release
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crypts from intestinal tissue fragments, the solution was vigorously pipetted 10-20 times.
The solution was passed through a 70 M cell strainer to remove clumps and centrifuged
at 800 rpm for 5 minutes. The pellet was resuspended in 5 mL DMEM (Fisher) containing
Glutamax (Life Tech), (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (Hepes; Life
Tech), and antibiotic/mycotic penicillin and streptomycin solution (Life Tech).
2.8.3

Isolation of colonic crypts

The entire colon was collected and flushed with PBS (Fisher). The colon was then opened
longitudinally and scraped using a glass cover slip. Once scraped, the colon was transferred
to a centrifuge tube and washed vigorously with PBS. The colon was resuspended in 10
mL of 3 mM EDTA in PBS and incubated at 4°C in a rotator for one hour. The colon was
removed from solution and cut into 0.5 mm pieces and resuspended in 10 mL of FBS. To
release crypts from colonic tissue fragments, the solution was vigorously pipetted 15-25
times. The solution was passed through a 100 µm cell strainer to remove clumps and
centrifuged at 800 rpm for 5 minutes. The pellet was resuspended in 5 mL DMEM
containing Glutamax, Hepes, and penicillin/streptomycin .
2.8.4

Counting and seeding crypts

The number of crypts in three 10 mL aliquots were counted and the appropriate volume of
solution to seed the number of wells required was calculated. This volume was taken and
resuspended in a 50:50 ratio with DMEM, followed by 50:50 dilution into the appropriate
volume of Matrigel (Fisher). Ninety-six well plates were pre-warmed in the incubator prior
to adding Matrigel.
2.8.5

Organoid media

Ninety-nine µL of organoid growth media (Table 5) was added to each well of the 96-well
plates. Plates were returned to the incubator immediately, and the media was changed every
4 days.
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Table 5 | Recipe for complete organoid culture medium.
Organoid Culture Medium

Volume

Penicillin/Streptomycin (100x )

1 mL

Hepes Buffer (100x)

1 mL

Glutamax (100x)

1 mL

N2 Supplement (100x)

1 mL

B27 Supplement (50x)

2 mL

Rspondin

2 mL

DMEM

2.8.6

100 mL

Diphtheria toxin treatment of organoids

Organoids were treated with 20 ng/mL of Diphtheria toxin (DT) every two days from day
10 to day 30 (Figure 15). Thirty µL aliquots of 2 ng/mL DT were prepared on ice from
100X stock (Sigma). Aliquots were stored at -80°C until ready for use. One µL stock was
added to 99 µL of media in each well.
2.8.7

Passaging organoids

Organoids were passaged every 10 days. Briefly, media was removed from each well and
resuspended with 100 µL of cold DMEM. Matrigel was disrupted using a 200 µL pipette
tip and pipetted up and down to free the organoids from the Matrigel. It was then pipetted
into a 15 mL centrifuge tube, wells were rinsed with an additional 100 µL of cold DMEM
and transferred to the tube. The organoids were centrifuged at 600 rpm for 5 minutes and
the pellet was resuspended in growth media and re-seeded.
2.8.8

Image acquisition & analysis of organoids

Phase contrast images of organoid wells were obtained at days 10, 20, and 30 using EVOS
FL Auto. Images were analyzed using ImageJ to quantify organoid number, area covered,
as well as organoid-formation efficiency. Organoid-formation efficiency was defined as
the ratio of the number of large colonies prior to passaging on day 20 and day 30 to the
number of clones on day 10. The threshold area for total colonies on day 10 was set as <2
x 105 m2 and for large colonies on day 30 as >2 x 105 m2 (equivalent to 20 cells).
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2.9

Statistical analysis

Descriptive data analysis was performed using Microsoft Excel. Comparison of means was
carried out using GraphPad Prism 6.0. Following normality testing, the appropriate
statistical test was carried out, as indicated in figures.
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Chapter 3
RESULTS
3.1

K19 labels a CSC population in an APCmin model

The presence of CSCs in CRC as well as many other cancers has become apparent over the
past years. Different populations of CSCs have been proposed in the literature based on the
expression of different markers. The most well-known population has been defined as
expressing Lgr5. However, it remains to be determined whether more than one CSC
population exists in tumours. Our preliminary data indicated that K19 may label a CSC
population. Therefore, to investigate whether K19 marks CSC population in a familial
model of colorectal cancer, K19-CreERT;R26TdTomato;APCmin mice were used. In this
model, the TdTomato gene is fused with a stop codon cassette that is floxed by two loxP
sites and is downstream of the R26 promoter region. In the absence of Cre, the TdTomato
gene is not transcribed due to the stop codon and K19-driven fluorescence is not evident.
When tamoxifen is administered, Cre is transcribed from the K19 promoter and the
recombination of the loxP sites takes place leading to the excision of STOP cassette,
followed by robust TdTomato fluorescence in K19 cells. To visualize K19 lineage tracing
in a familial model of colorectal cancer, these mice were crossed with the APCmin mice.
APCmin mice spontaneously generate tumours due to loss of heterozygosity of the APC
allele. The majority of these tumours are found in the small intestine, however a small
proportion arise in the colon.

Tumours from 6-month old K19-CreERT;R26TdTomato;APCmin mice were analyzed for
lineage tracing via histological analysis at 24 hours (n = 3) , 10 days (n = 2) and 4 weeks
(n = 3) post-tamoxifen. The percentage of tumour area traced was calculated using ImageJ.
In the small intestine, we found that a small proportion of tumour area was traced red 24
hours after administration of tamoxifen (2.913 ± 1.547). From 24 hours to 10 days posttamoxifen, the red cell population expanded to encompass an average of 21.59 ± 2.143%
of tumours, which was not significantly different compared to 4 weeks post-tamoxifen
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(18.26 ± 3.903%) (Figure 15). This indicates that K19+ stem cells clonally expanded in
established tumours, suggesting K19 may label a CSC population.
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Figure 15 | K19 labels a cancer stem cell population in the small intestine of APCmin
mice. Experimental protocol (A) used to analyze K19+ cells in adenomas from K19CreERT;TdTomato;APCmin mice. Low power representative images of adenomas (Scale
bars, 1000 m) in the small intestine at 24h (B), 10d (C) and 4 weeks (D) post tamoxifen
are shown. High power view of adenomas (Scale bars, 200 m) in the small intestine are
shown by immunofluorescence (left) and H&E (right). (E) Quantification of K19+ cells
traced in adenomas as area over time. There was a significant increase in the area of tumour
traced between 24h and 10d, while no significant was observed between 10d and 4w.
Although significant between 24h and 10d, it is important to note that this comparison may
have low power due to an n of 2 in the 10d group. Data is presented as mean ± SE; n ≥ 2;
analyzed by one-way ANOVA followed by Tukey’s post hoc test for multiple
comparisons; * p < 0.05.

3.2

K19 may label a CSC population in an AOM DSS model

In order to address whether K19 labels a CSC population in a colitis-associated model of
colorectal cancer, tumours from AOM/DSS treated K19-CreERT;TdTomato mice were
analyzed for lineage tracing at 24 hours (n = 4) , 10 days (n = 4) and 4 weeks (n = 4) posttamoxifen. At 24 hours post-tamoxifen, a small proportion of tumour area was traced red
(2.034 ± 1.551%). However, the proportion of red cells did not significantly increase from
24 hours to 10 days (7.083 ± 2.692%) and 4 weeks (5.025 ± 4.085%) (Figure 16). These
results show lack of clonal expansion in K19 cells in the AOM/DSS-derived tumours.
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Figure 16 | K19 may label a CSC population in an AOM DSS model. Experimental
protocol (A) used to analyze K19+ cells in adenomas from AOM DSS treated K19CreERT;TdTomato mice. Low power representative images of adenomas (Scale bars, 1000
m) in the colon at 24h (B), 10d (C) and 4 weeks (D) post-tamoxifen are shown. High
power view of adenomas (Scale bars, 200 m) in the colon are shown by
immunofluorescence (left) and H&E (right). (E) Quantification of K19+ cells traced in
adenomas as % area over time. No significant increase in the area of tumour traced over
time was observed. Data is presented as mean ± SE; n = 4 per group; analyzed by one-way
ANOVA; * p < 0.05.

3.3
3.3.1

Ablation of Lgr5+ cells has no effect on tumour initiation
or growth in vivo
Diphtheria toxin dose characterization

To confirm effective ablation of Lgr5+ cells in the intestine and colon of Lgr5-DTR-eGFP
mice, 200 mL or 500ng of DT dissolved in 200 mL 0.9% saline was administered i.p. twice
a week for two weeks (Figure 17; A). Twenty-four hours post administration of the last
dose, tissues were prepared for histological analysis and analyzed for the presence of eGFP.
As expected in the DT treated group, no eGFP (green) cells were present (Figure 17; B).
This is compared to the saline treated group, where an abundance of eGFP (green cells)
were found in the crypt base where Lgr5+ cells reside.
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Figure 17 | Diphtheria toxin dose characterization. (A) Experimental protocol. (B) Low
power representative immunofluorescence (Scale bars, 200 m) of small intestine and (C)
colonic crypts in control (left) versus DT treated (right) Lgr5-DTR-eGFP mice (insets 20x
magnification). As expected with administration of DT, all Lgr5+ cells are ablated.
3.3.2

Ablation of Lgr5+ cells has no effect on tumour initiation or growth in vivo

To examine the effect of Lgr5+ cell ablation on tumour initiation and growth in vivo,
AOM/DSS treated WT and Lgr5-DTR-eGFP mice were administered 500 ng of DT or
saline i.p twice a week, 3-weeks after AOM and until the end of the experiment (20 weeks
post-AOM) (Figure 18, A). Mice do not express the diphtheria toxin receptor (DTR) and,
therefore, are not susceptible to diphtheria toxin (DT). Thus expression of DTR in a Lgr5
cell population allows for selective ablation of these cells upon DT administration. Cohorts
of WT or Lgr5-DTR-eGFP experimental (DT treated) and control (saline treated) mice
were compared (n > 10 per group) with respect to histology and tumour burden (number
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and volume) at 20 weeks. As expected, histological analysis of adenomas from Lgr5
negative WT mice revealed no GFP expression (Figure 18, B and C), while adenomas of
Lgr5 positive mice treated with saline had robust GFP signal (Figure 18, D). This is in
contrast to Lgr5 positive mice treated with DT that did not express GFP (Figure 18, E).
These results indicate that Lgr5 + cells were effectively ablated. Importantly, when tumour
burden was analyzed, no significant differences were observed in tumour number (Figure
18, F) or tumour volume (Figure 18, G). This suggests that another CSC population besides
Lgr5+ may contribute to tumour initiation and growth, as a complete loss of Lgr5+ cells
has no effect on tumour burden.
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Figure 18 | Ablation of Lgr5 cells has no effect on tumour initiation or growth. (A)
Experimental protocol. Low power representative immunofluorescence (Scale bars, 1000
m) of colonic tumours from (B) WT/Saline, (C) WT DT, (D) Lgr5+/Saline and (E)
Lgr5+/DT treated mice are shown. High power images (Scale bars, 200 m) are shown by
immunflourescence (left) and histology (right) for colonic tumours (F) The number of
tumours and (G) tumour volume did not vary significantly between groups; p > 0.05.
Results presented as mean ± SE; n ≥ 10. One-way ANOVA was used for statistical
analyses.

3.4 Intestinal and colonic K19+ APC floxed organoids give
rise to spheroids
Asfaha et al. (2015) reported that when intestinal crypts from K19-CreERT;APCf/f mice
were cultured following tamoxifen administration, recombined APC floxed organoids
appeared as spherical structures, which were easily distinguishable morphologically from
normal budding crypt structures. However, it was unclear whether colonic APC floxed
crypts cultured from K19-CreERT;APCf/f mice would give rise to spheroids in vitro. To
investigate this, intestinal and colonic crypts from K19-CreERT;APCf/f mice were
cultured 48 hours after tamoxifen administration (Figure 19, A). As expected intestinal
crypts contained APC floxed K19+ cells gave rise to spheroid structures that were easily
distinguished from normal wild-type budding crypt structures (Figure 19, B). Similarly,
colonic crypts from recombined APC floxed K19+ cells appeared as spheroid structures,
which were also easily distinguishable morphologically from normal budding crypt
structures (Figure 19, C). Moreover, K19+ cells in which APC was floxed produced
organoids that could be maintained in culture even in the absence of R-spondin (Figure
20/21).
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Figure 19 | Intestinal and colonic K19+ floxed organoids give rise to spheroids. (A)
Experimental protocol. (B) Representative phase contrast images of intestinal and colonic
(C) crypts cultured from K19-CreERT;APCf/f mice 48 hours after tamoxifen. Note Wild
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Type (WT) organoids display a budding morphology while APCf/f organoids form
spheroids. Scale bars, day two (100 m), day four (200 m) and day eight (400 m).

3.5

Ablation of Lgr5+ cells has no effect on intestinal

or

colonic spheroid growth
To determine the effect of Lgr5+ cell ablation on tumour growth in established K19
tumours in vitro, Lgr5-DTR-eGFP mice were crossed to K19-CreERT;APCf/f mice to
generate Lgr5-DTR-eGFP;K19-CreERT;APCf/f (L5DKA) mice. Briefly, treatment of
these L5DKA mice with tamoxifen induces a loss of APC specifically in K19 cells and
allows for ablation of Lgr5+ cells with DT administration. Our lab previously demonstrated
that following tamoxifen treatment, intestinal cells cultured from L5DKA mice give rise to
spherical “tumour” organoids in vitro in 48 hours. To determine the effects of Lgr5+ cell
ablation on K19 spheroids, both intestinal and colonic crypts from tamoxifen treated
L5DKA mice were cultured to monitor their growth and spheroid forming capacity with
administration of DT. The organoids generated were treated with 20 ng/mL of DT
(experimental) or vehicle (control) from d10 to d30. Additionally, a subset of spheroids
was treated with DT from d10 to d20 and vehicle from d20 to d30 (Figure 20, A).
Subsequently, the total number of spheroids, spheroid area and spheroid formation capacity
were analyzed over time for small intestine and colonic spheroids. In the small intestine
and colon, there was no significant difference (p > 0.05) in the total number of spheroids,
tumour area or organoid forming efficiency between control, DT or DT removed groups at
D10, D20 or D30 (Figure 20 and 21, C, D, E). Interestingly, there also was no change in
tumour area between all groups (p > 0.05) (Figure 20 and 21 D).

As a control, intestinal and colonic crypts from tamoxifen-treated K19-CreERT;APCf/f
mice were cultured at the same time as L5DKA mice using the same protocol to monitor
their growth and spheroid forming capacity with administration of DT or vehicle. My
results show no significant difference (p > 0.05) in the total number of spheroids, tumour
area or organoid forming efficiency between control, DT or DT removed groups at D10,
D20 or D30 (Figure 22 and 23, C, D, E). This demonstrates the DT administration itself
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has no effect on intestinal or colonic spheroids, providing further support to the findings in
Figure 20.

These results highlight that with a complete loss of Lgr5+ cells in K19+ APC floxed
intestinal and colonic spheroids, there is no effect on tumour number, growth, or organoid
forming efficiency. This suggests that another CSC population besides Lgr5+ CSC may
establish intestinal and colonic tumours and contribute to tumour growth. Moreover,
organoid-forming efficiency reflects the surviving fraction of stem cells among crypt cells
as organoids are derived from stem cells. Therefore, despite continuous ablation of Lgr5+
CSCs (even after passaging), another CSC population must exist in intestinal and colonic
tumours, that allows spheroids to establish themselves. Taken together, these results
suggest that K19+ APC floxed spheroids are composed of a heterogeneous population
whereby Lgr5 may be dispensable.
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Figure 20 | Ablation of Lgr5 cells has no effect on small intestine spheroid growth. (A)
Experimental protocol. (B) Representative phase contrast images of organoid cultures
(scale bars, 1000 m). (C) Quantification of the number of spheroids, spheroid area (D),
and spheroid forming efficiency (E). No significant differences were observed between
treatment groups. Results presented as mean ± SE; n = 3. A two-way ANOVA followed
by Tukey’s post-hoc test for multiple comparisons was used for statistical analyses.
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Figure 21 | Ablation of Lgr5 cells has no effect on colonic spheroid growth. (A)
Experimental protocol. (B) Representative phase contrast images (scale bars, 1000 m) of
organoid cultures. (C) Quantification of the number of spheroids, spheroid area (D), and
spheroid formation efficiency (E). Results presented as mean ± standard error of the mean;
n = 3. No significant differences were observed between treatment groups. A two-way
ANOVA followed by Tukey’s post-hoc test for multiple comparisons was used for
statistical analyses.
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Figure 22 | Diphtheria toxin has no effect on WT small intestine spheroids. (A)
Experimental protocol. (B) Representative images of organoid cultures (scale bars, 1000
m). (C) Quantification of the number of spheroids, spheroid area (D), and spheroid
formation efficiency (E). Results presented as mean ± standard error of the mean; n = 3.
No significant differences were observed between treatment groups. A two-way ANOVA
followed by Tukey’s post-hoc test for multiple comparisons was used for statistical
analyses.
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Figure 23 | Diphtheria toxin has no effect on WT colonic spheroids. (A) Experimental
protocol. (B) Representative images of organoid cultures (scale bars, 1000 m). (C)
Quantification of the number of spheroids, spheroid area (D), and spheroid formation
efficiency (E). Results presented as mean ± standard error of the mean; n = 3. No significant
differences were observed between treatment groups. A two-way ANOVA followed by
Tukey’s post-hoc test for multiple comparisons was used for statistical analyses.
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Chapter 4
DISCUSSION
The purpose of this thesis was to determine if the colorectal cancer stem cell pool
encompasses different stem cell phenotypes, much like the normal intestinal epithelium.
To identify additional CSCs, I analyzed genetic lineage tracing from K19+ cells in vivo in
multiple mouse models of CRC. To provide further evidence for the presence of multiple
cell types, my experiments were followed by ablation of a known CSCs (marked by Lgr5
expression) in established tumours in vivo and in vitro. My rationale for this approach was
based on accumulating evidence which implicated the role of multiple CSCs in CRC, as
well as our lab’s preliminary findings that K19 may label a CSC population (unpublished
studies). My findings support my initial hypothesis that K19 identifies a CSC population
distinct from the previously identified Lgr5+ CSCs. Although further studies are necessary
to determine whether K19 is essential for tumour growth, data presented here provides
insight into the seemingly diverse CSC pool present in CRC tumours.

4.1

K19 labels a CSC population in an APCmin model

Previous data from our lab identified K19 as a stem cell marker in the small intestine and
colon, distinct from Lgr5+ cells that can give rise to tumours (Asfaha et al. 2015).
Moreover, K19 is amplified in solid tumours making it an ideal candidate CSC marker
(Lapouge et al., 2011). As such, I hypothesized that K19 would label a CSC population in
a mouse model of FAP-CRC. Genetic lineage tracing was used to evaluate CSC potential
(i.e. the ability to self-renew and differentiate) to circumvent the drawbacks of traditional
serial transplantation assays.
To determine whether K19 labels a CSC population, I analyzed the percentage of intestinal
and colonic tumour area traced over time in K19-CreERT;R26TdTomato;APCmin mice.
In the small intestine, I found that a small tumour area (2%) was traced red at 24 hours
after tamoxifen administration, indicating that it was derived from the labeled K19 cells.
Interestingly, this clonal population expanded significantly to make up approximately 20%
of tumours by day 10. No further increases were noted at 4 weeks. These set of results
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indicate that single traced clones are capable of giving rise to cell lineages that are labeled
long-term. Long-term labeling is suggestive of self-renewal, given the highly proliferative
nature of tumours. As is the case with Lgr5+ CSCs, sorted K19+ intestinal tumour cells
have not been studied in a serial transplantation assay to determine self-renewal or
tumourigenic capacity. It should be noted that applicability of serial transplantation assays
to solid tumours is controversial. The appearance of Paneth cells in traced lineages suggests
the ability of K19 CSCs to differentiate. However, immunohistochemical staining to
confirm the presence of Paneth cells or other differentiated lineages has not been carried
out. Regardless, the ability of K19 to form single traced clones capable of giving rise to
cell lineages (that appear to contain Paneth cells with eosinophilic granules in histological
sections) and are labeled long term suggests multipotency and self-renewal. Consequently,
my findings represent the first study to identify K19 as a marker for CSCs in intestinal
tumours of APCmin mice.
Interestingly, an elegant study conducted by de Sousa e Melo et al demonstrated that Lgr5+
ablation restricts primary tumour growth but does not result in tumour regression (de Sousa
e Melo et al., 2017). The authors go on to propose that tumours may be maintained by an
Lgr5 negative population capable of replenishing the Lgr5+ CSC pool, which leads to rapid
initiation of tumour growth upon removal of treatment (de Sousa e Melo et al., 2017). This
is similar to what has been observed in the normal intestine, where homeostasis is
maintained by reserve stem cell populations if Lgr5 cells are lost. In contrast to primary
lesions, they found that Lgr5 plays a critical role in the development of metastasis as little
evidence of metastatic lesions was found post Lgr5 ablation (de Sousa e Melo et al., 2017).
Together, this data highlights that different CSC populations may play different roles in
primary versus metastatic tumour growth or even across different stages of CRC.
Moreover, when taking into consideration that K19 labels a CSC population in the APCmin
model, our data provides support that K19 labels a CSC population in primary tumour sites.
The APCmin mouse model does not metastasize and is most representative of early stage
CRCs. Of note, the model used in the study by de Sousa e Melo et al contained mutations
in APC as well as KRAS. However, it would be highly relevant and interesting for future
studies to investigate the role of K19 and Lgr5 at different stages of CRC progression.
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Additionally, future studies should investigate whether K19 is essential in primary tumours
through genetic ablation studies.

4.2

K19 may label a CSC population in the AOM/DSS
model of CRC

To investigate whether K19 labels a CSC population in a colitis-associated model of CRC,
I analyzed genetic lineage tracing from K19-CreERT;R26TdTomato mice treated with
AOM/DSS at various time points post-tamoxifen administration. I hypothesized that K19
would label a CSC population in this model and that K19+ cell-derived clones would
expand and persist in tumours. Initially, I observed a small population of clones in the
tumours. However, the clones did not expand to give rise to more differentiated cell types
over time but persisted. These results were not expected. There are several possible
explanations for this observation as the CSC phenotype is likely influenced by a variety of
factors, including the tissue microenvironment, and the accumulation of mutations at
various progressive stages. A study conducted by de Sousa e Melo et al. demonstrated that
Lgr5 labelled CSCs are influenced by both tissue location and tumour microenvironment
(de Sousa e Melo et al., 2017). Contrary to their initial expectations, ablation of Lgr5 CSCs
in primary tumours did not lead to tumour regression. However, they did find that Lgr5
cells play a role in the establishment of liver metastasis. The authors suggested that
different “biological cues” mediated CSCs in primary and metastatic sites leading to
proliferation of certain CSC populations. In accordance with this study and the results I
obtained using the K19 APCmin model, K19 may play a more important role in the earlier
stages of CRC. A key distinction between my studies and that by de Sousa e Melo et al. as
well as other is that only APC is mutated in the APCmin model compared to -catenin as
well as KRAS alterations in in the AOM DSS models (Takahashi and Wakabayashi, 2004).
These studies highlight the importance of the tumour microenvironment (inflammation,
primary vs metastatic sites) and genetic mutations (for example, APC vs APC/KRAS) in
contributing to the CSC phenotype observed.
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4.3

Ablation of Lgr5+ cells has no effect on tumour
initiation or growth

Previous research has suggested that the CSC pool likely encompasses different cell
phenotypes in a dynamic equilibrium with each other and that elimination of Lgr5+ CSCs
might disrupt tumour biology to alter tumour growth but not eradicate disease. These
findings, in combination with my results from sections 3.1, prompted me to examine the
effects of Lgr5+ CSC ablation on tumour initiation and growth in an AOM DSS model. I
hypothesized that ablation of Lgr5 cells would have no effect on tumour initiation or
growth. Previously, it was shown that short-term administration of high doses of diphtheria
toxin was associated with liver toxicity and subsequent lethality in 10 days (Asfaha et al.,
2015). Therefore, it was necessary to first establish a protocol that effectively ablated Lgr5
cells at a lower dose for long-term use. Subsequently, I found that 500 ng of DT
administered twice a week effectively ablated Lgr5 cells. This was indicated by the
presence of Lgr5-GFP+ cells in the vehicle-treated group versus no Lgr5-GFP+ cells in the
DT-treated group (Figure 17). Moreover, no detrimental effect on intestinal or animal
viability was observed and ensuing long term experiments on the effects of Lgr5 ablation
throughout tumour initiation and growth were conducted.
In support of my hypothesis, I found that Lgr5+ CSCs are dispensable for tumour initiation
as well as maintenance. Furthermore, efficiency of ablation was confirmed through
analysis of histological sections post-ablation. I observed Lgr5-GFP+ cells in vehicletreated Lgr5-DTR-eGFP mice, while no Lgr5-GFP+ cells were observed in Lgr5-DTReGFP mice treated with DT or untreated controls. The results from this study demonstrate
for the first time that more than one CSC population functionally contributes to tumour
initiation and growth in a colitis-associated model of CRC. Similarly, these findings are
also supported by two recent studies by independent groups that demonstrated little effect
on tumours following ablation of Lgr5 cells. In one study de Sousa e Melo et al., showed
that ablation of Lgr5 in primary tumours had no effect on tumour growth suggesting an
Lgr5 negative population is capable maintaining tumour growth (de Sousa e Melo et al.,
2017). In another study, it was shown that Lgr5 ablation was only effective temporarily
(Shimokawa et al., 2017). Furthermore, targeted ablation of Lgr5+ cells using an Lgr5
antibody directed chemotherapeutic in the APCmin mouse model had no effect on tumour
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burden (Junttila et al., 2015). These studies in combination with my findings demonstrate
that in some tumour models, the CSC pool encompasses different cell phenotypes.
Unlike the present study, previous studies investigating the ablation of Lgr5 in tumour
models did not focus on tumour initiation or utilize immunocompetent mice. As discussed
earlier, the tumour microenvironment plays an important role in regulating CSC function.
This is of the utmost importance when considering the phenotype of CSCs, particularly in
colitis-associated cancer - as the immune system plays a critical role in regulation of the
tissue microenvironment. It is important to note, that animal models do not recapitulate all
types of human colorectal cancer and these results do not recapitulate the results that might
occur at different stages of CRC. As such, the results obtained in this study are likely
reflective of this particular model.

4.4 Intestinal and colonic K19+ APC floxed organoids give
rise to spheroids
In 2009, Sato et al. demonstrated that single Lgr5-eGFP+ CBC cells isolated using FACS
and plated in a Matrigel-based three-dimensional culture system gave rise to self-renewing
epithelial organoids (Sato et al., 2009). This method was a monumental breakthrough in
the field of intestinal stem cells. Later on, it was adapted to culture Lgr5+ CBC that
contained a mutation in the APC gene. Interestingly, loss of APC function in Lgr5 cells
gave rise to organoids that had a cystic morphology, compared to the normal budding
structure. It was later determined that these organoids were representative of early stage
colorectal cancers. Subsequently, the culture protocol was modified, allowing for the
addition of several mutations found in later stages of colorectal cancer, as well as the
eventual culture of human colorectal tumours (Sato et al., 2011; Shimokawa et al., 2017).
Since 2009, multiple “tumour organoid” models have been adapted from this initial
protocol.

In particular, Asfaha et al. adapted the Sato protocol to establish a tumour organoid
protocol derived from intestinal crypts of K19-CreERT;APCf/f mice. Treatment of these
mice with tamoxifen induced loss of APC specifically in K19+ cells, and intestinal crypts
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cultured from these mice gave rise to tumour spheroids in vitro after 48 hours (Asfaha et
al., 2015). However, it remained unclear whether colonic crypts from these mice would
give rise to colonic tumour spheroids. Based on the expression of K19+ ISCs in both the
normal and intestinal and colonic crypt, I hypothesized that loss of APC in colonic K19
cells would give rise to colonic tumour spheroids, similar to the small intestine. My results
showed that when colonic intestinal crypts were cultured two days after in vivo tamoxifen
administration, large cystic structures appeared. The same phenomenon was observed in
intestinal crypts that were cultured identically. As described previously, APC floxed
organoids are easily distinguishable from non-recombined crypts that form normal budding
structures (as shown in Figure 19). Of note, K19+ APC floxed organoids are maintained in
the absence of R-spondin. In normal, non-mutated organoids, R-spondin is required for
amplification of Wnt signalling and organoid survival. Accordingly, when R-spondin was
removed (Figures 20 and 21) from both intestinal and colonic organoids, only APCf/f
spheroids survived. Thus indicating that both colonic and intestinal tumour spheroids were
derived from K19-CreERT;APCf/f crypts. It is important to note, however, that nuclear colocalization of β-catenin has not been validated in this model. Despite this limitation,
selection of tumour organoids with R-spondin provides functional evidence of APC loss
of function.

4.5 Ablation of Lgr5+ cells has no effect on intestinal or
colonic spheroids
As mentioned in section 4.3, previous research has suggested that the CSC pool likely
encompasses a dynamic cell population as elimination of Lgr5+ CSCs in some CRC
models has limited effects. My results in a colitis-associated model of CRC are supportive
of this notion. However, it remains unknown whether Lgr5 CSCs are dispensable in
established tumours representative of early stages of CRC, and unrelated to inflammation.
As such, I hypothesized that loss of Lgr5 in established APCf/f tumours (model of early
stage CRC) would have no effect on spheroid number, growth or formation efficiency. I
crossed K19-CreERT;APCf/f mice to Lgr5-DTR-eGFP mice to generate an Lgr5-DTReGFP;K19-CreERT;APCf/f model. As mentioned in the previous section, when intestinal
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and colonic crypts are cultured after tamoxifen treatment, cystic tumour organoids form
due to the loss of APC in K19+ cells. Additionally, the presence of Lgr5-DTR-eGFP allows
for the conditional and specific ablation of Lgr5 cells in established K19+ cell derived
APCf/f tumours. Therefore, I treated organoid cultures with DT once tumour organoids
were established for 10 days. Following the 10 days, DT was removed from a subset of
organoids to determine the effects on growth and stem cell activity. As a control, K19CreERT;APCf/f mice were cultured at the same time to ensure DT alone did not have an
effect on tumour number, organoid area or spheroid formation efficiency. My results show
that ablation of Lgr5 cells in intestinal and colonic tumour spheroids had no effect on the
number, area or spheroid formation efficiency between control and DT groups across all
time points (Figure 20, 21). Importantly, no effect on spheroid number and area indicates
that an Lgr5- cell population is contributing to spheroid growth and Lgr5 cells are
dispensable in this model. This highlights that another CSC population must reside in these
spheroids that allows continuous establishment despite constant ablation of Lgr5+ cells
even after passaging. This is consistent with my findings presented in section 3.3.2.
Additionally, my results from section 3.1, highlight that in an APCmin model, where only
APC is mutated, K19 labels a CSC population, thereby corroborating the existence of
another CSC population in the early stages of CRC. Future studies should directly examine
K19 lineage tracing in addition to Lgr5 ablation with an APCmin or APCf/f model to
conclusively determine this.

Unexpectedly, there was no difference between all groups when DT was removed from a
subset of spheroids. This is in contrast to the findings of de Sousa e Melo et al., in which
discontinuation of DT mediated Lgr5 ablation led to rapid tumour organoid regrowth (de
Sousa e Melo et al., 2017). Importantly, this is likely due to differences in experimental
models. Our model is reflective of the early stages of CRC, in which only APC is mutated.
In contrast, their model is representative of later stages of CRC and included mutations in
the KRAS, p53 and SMAD pathways. These results suggest K19 may be an important
target in prevention or treatment of earlier stages of CRC. Although unlikely, another
potential explanation is that the dose of DT used did not sufficiently ablate Lgr5+ cells. As
such,

future

studies

should

confirm

ablation

of

Lgr5+

cells

possibly by
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immunohistochemical or mRNA analysis of DT-treated vs control organoids. It is
important to note, however, that the dose of DT used in my study (20 ng) was determined
to effectively ablate Lgr5 CBC cells in intestinal organoids by mRNA analysis (Asfaha et
al., 2015). Interestingly, in this published study, mRNA analysis also revealed an increase
in K19 mRNA expression upon DT mediated ablation of Lgr5. This suggests that the same
phenomenon may be occurring in established APCf/f spheroids in vitro, although, this
needs further verification. Lastly, no differences were observed between control, DT, or
DT removed groups in intestinal and colonic spheroids derived from Lgr5-DTR-eGFP
negative K19;APCf/f controls (Figure 22, 23). This suggests that administration of DT
alone has no effect on spheroid number, growth or formation efficiency. Taken together,
these findings provide evidence that more than one CSC population exists in an early CRC
model. This highlights that in some models, the CSC population represents a dynamic cell
population in delicate equilibrium.

4.6 Implications and future directions
The studies outlined here advance our understanding of cancer biology in two very
meaningful ways: (1) I determined that the CSC pool encompasses a variety of cell
phenotypes; and (2) I determined the relative contributions of these populations to tumour
growth by ablating a known CSC population. These two concepts have important
implications for the design of anti-tumour therapies. On the one hand, drugs targeted at
malignant sub-populations with CSC properties may have important therapeutic effects.
However, these effects may vary depending on how permissive the host tissue is to
dynamic interconversion between CSC phenotypes and functional differences that may
exist between CSC populations. Therefore, drugs or radiation aimed too narrowly at only
one CSC phenotype might translate to only transient, short-lived clinical benefits and
eventually fail to cure patients. Although these concepts increase the level of complexity
for developing new cancer treatments, my research may lead to an improved understanding
of the systems that governs the growth, multi- lineage differentiation, dynamic turnover
and regenerative response to tumour tissues. Our lab has developed unique transgenic
mouse models that are clinically relevant because they are immunocompetent and allow us
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to selectively kill a known cancer stem cell in vivo. Moreover, my findings suggest that a
diverse population of CSCs exist in early and colitis-associated colorectal cancer mouse
models. This may suggest that CSCs are governed by the tumour microenvironment or
genetic mutations. Consequently, this improved understanding of CSCs will help define
new molecular targets for different phenotypic subgroups of CSCs or block the sources of
CSCs simultaneously to achieve complete elimination of cancer.

Despite the insights into colorectal cancer CSCs in this thesis, several questions could not
be directly answered. Importantly, although it was demonstrated that K19 labels a cancer
stem cell population in the APCmin model, it remains unknown whether K19 is essential
for tumour growth or whether K19 is influenced by the tumour microenvironment directly.
These questions could be answered through genetic ablation studies of K19 and
manipulation of the tumour microenvironment through in vitro studies. Additionally, the
question of whether K19 CSCs drive chemotherapy or radiation resistance could not be
answered in this thesis. Future experiments evaluating the tumorigenicity of K19 in
different CRC models could provide more evidence to answer this question.

The results in this thesis warrant further exploration and direct comparison of different
CSC phenotypes observed in various CRC models as well as stages of progression. This
would help to determine essential therapeutic targets as well as the relative contributions
of each population to therapy resistance, metastasis and patient survival. Therefore, future
experiments should focus on the identification, evaluation and comparison of verified CSC
populations to answer this question.

4.7 Limitations
The first aim of this thesis was to determine if K19 labels a cancer stem cell population. A
potential limitation of aim one is the confirmation of CSC multipotency in lineage tracing
models of CRC. While my initial lineage tracing experiments revealed that K19 labels a
CSC population in the APCmin model, possibly capable of giving rise to Paneth cells,
further experiments are necessary to determine multipotency. In this sense,
immunohistochemical analysis of differentiated cell markers (e.g. lysozyme) in tumours
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would complement these studies. Likewise, throughout this thesis, genetic lineage tracing
analysis was used to determine stemness. However, it would be interesting to assess the
CSC potential of these cell populations using serial transplantation assays as a secondary
measure of the ability of these cells to self-renew. Perhaps, this may be conducted in vitro
using serial culture of organoids. However, this approach may not be as powerful as genetic
lineage tracing. It is also important to note that the cre-lox lineage tracing models utilized
in this study demonstrate genetic mosaicism. As a result of this, it is likely that the K19+
population labelled in my studies is reflective of only a subset of the true population. The
CSC marker identified in this thesis was not characterized as distinct from Lgr5 cells
through the appropriate lineage tracing/genetic ablation studies because of the extensive
nature of the studies. Most importantly, the long-term side effects or targeting these novel
CSC populations was not investigated. This is an important issue to consider before
investigating these novel CSC markers as potential therapeutic targets, as K19+ cells share
expression with both normal and cancerous tissues.

The second aim of this thesis was to assess the effects of Lgr5+ cell ablation on tumour
growth in vivo and in vitro. In the in vivo model, no effect was observed on tumour
initiation and growth. However, the mouse model used in this experiment does not
recapitulate all types of human colorectal cancer and at all stages. Therefore, the results
obtained are likely only reflective of this particular model. Importantly, this limitation is
applicable to every mouse CRC model used in this thesis. As such human colorectal cancer
organoids or additional animal models should be used to investigate these processes at
various stages and types of CRC.

When analyzing the ablation of Lgr5 in vitro, I found no effect on spheroid number, growth
or formation efficiency. Although the dose used was previously demonstrated to be
effective by Asfaha et al., a potential limitation of this experiment is that confirmation of
DT-mediated ablation by mRNA or immunohistochemical analysis was not carried out.
Furthermore, it would have been optimal to conduct cell viability assays to determine the
appropriate dose of DT. Lastly, in the organoid formation assays clumps of cells were
plated rather than individual cells. It may have been more accurate to generate single cell
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cultures from organoids which may be achieved by using TrypLE, however, this process
is much costlier and time consuming.

4.8 Conclusion
The cancer stem cell hypothesis suggests that CSCs are the driving force behind tumour
progression and metastasis, making them ideal therapeutic targets. Previous research
identified Lgr5 as an important marker of CSCs in CRC. However, effective treatment of
CRC patients depends on the identification of cells responsible for tumour initiation and
progression. This was precisely the motivation of my studies. I found that K19 labels
mouse intestinal CSCs in tumours arising in a model that recapitulates the early stages of
human CRC. Moreover, selective ablation of Lgr5 had no effect on tumour initiation or
growth in vivo or in vitro. These results clearly demonstrate that additional CSC
populations, beyond Lgr5+ cells, exist in intestinal and colonic tumors and are important
for tumour initiation and growth.
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APPENDIX I: CHEMICAL LIST AND SUPPLIERS
CHEMICAL

SUPPLIER

TAMOXIFEN

Sigma

DAPI

Fisher

AOM

Sigma

DIPHTHERIA TOXIN

Sigma

TAQQ FROGGAMIX

FroggaBio

TAE

Fisher

NUCLEASE FREE H2O

FroggaBio

AGAROSE

Fisher

ETHIDIUM BROMIDE

Sigma

DSS

Gojira

CORN OIL

Sigma

PBS

Fisher

4% PFA

Santa Cruz

OCT

Fisher

EOSIN

Fisher

HEMATOXYLIN

Cedarlane

XYLENES

Fisher

MOUNTING MEDIUM DAPI

Vectashield

MOUNTING MEDIUM H&E

Toluene - Fisher

EDTA

Fisher

TRITON X 100

Fisher

FBS

Fisher

DMEM

Life Tech

GLUTAMAX

Life Tech
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HEPES

Life Tech

PEN/STREP

Life Tech
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APPENDIX II: PREPARATION OF SOLUTIONS
Tail Lysis Buffer – 25mM NaOH/0.2mM EDTA
10M NaOH

125mL

0.5M EDTA

20 mL

MilliQ Water

49.8 mL

1.

Add 125 mL of 10M NaOH + 20mL 0.5M EDTA to 50 mL centrifuge tube.

2.

Fill up to 50 mL of MilliQ water.

Tail Neutralization Buffer – 40mM Tris HCL (pH 5.5)
Tris HCL

315.12 mg

MilliQ water

50 mL

1.

Add 315.12 mg of Tris HCL to 50 mL centrifuge tube.

2.

Fill MilliQ water up to 45 mL

3.

Adjust pH to 5.5 using 10M NaOH and HCL

4.

Fill milliQ water up to 50 mL
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APPENDIX III: PCR CONDITIONS AND PRIMERS
K19-CreERT
CYCLE STEP

TEMP (°C)

TIME

CYCLES

Initial Denaturation

94

5min

1

Denaturation

94

30s

35

Annealing

55

30s

Extension

72

30s

Final Extension

72

7min

Hold

4

∞

1

Primers:
F- TCTCCCTCCTCATCATGTCC
R- CATGTTTAGCTGGCCCAAAT
APCf/f
CYCLE STEP

TEMP (°C)

TIME

CYCLES

Initial Denaturation

94

5min

1

Denaturation

94

30s

35

Annealing

60

30s

Extension

72

30s

Final Extension

72

7min

Hold

4

∞

1

Primers:
F- GAGAAACCCTGTCTCGAAAAAA
R- AGTGCTGTTTCTATGAGTCAAC

Rosa26-tdTomato
CYCLE STEP

TEMP (°C)

TIME

CYCLES

Initial Denaturation

94

5min

1

Denaturation

94

30s

35

Annealing

61

30s

Extension

72

30s

100

Final Extension

72

7min

1

Hold

4

∞

TEMP (°C)

TIME

CYCLES

Initial Denaturation

94

5min

1

Denaturation

94

30s

35

Annealing

61

30s

Extension

72

30s

Final Extension

72

7min

Hold

4

∞

Primers:
WT F – AAG GGA GCT GCA GTG GAG TA
WT R - CCG AAA ATC TGT GGG AAG TC
Mut F – GGC ATT AAA GCA GCG TAT CC
Mut R - CTG TTC CTG TAC GGC ATG G

Lgr5-DTR
CYCLE STEP

1

Primers:
F – AGAAGCCGGTGGAGAAGAG
R - GCTTGTGGCTTGGAGGATAA

APCmin
CYCLE STEP

TEMP (°C)

TIME

CYCLES

Initial Denaturation

94

5min

1

Denaturation

94

30s

35

Annealing

55

30s

Extension

72

1min

Final Extension

72

1min

Hold

4

∞

Primers:
F – TTC TGA GAA AGA CAG AAG TTA
R - TTC CAC TTT GGC ATA AGG C

1
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Lgr5
CYCLE STEP

TEMP (°C)

TIME

CYCLES

Initial Denaturation

94

5min

1

Denaturation

94

30s

35

Annealing

58

40s

Extension

65

1:10 min

Final Extension

65

3min

Hold

4

∞

Primers:
F - CACTGCATTCTAGTTGTGG
R – CGGTGCCCGCAGCGAG

1

102
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